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 ABSTRACT 
 
 
The neural precursor cell expressed developmentally down-regulated gene 4 
(NEDD4) is a HECT-type E3 ubiquitin ligase that has received broad attention in recent 
years. Many of its reported substrates are active players in metabolism, implying a 
potential role of NEDD4 itself in metabolic regulation. Since homozygous Nedd4 
deletion leads to embryonic or perinatal lethality, we investigated the function of NEDD4 
in metabolic regulation in vivo, using Nedd4-haploinsufficient mice in a high fat diet-
induced obesity (HFDIO) model. 
 
Our studies show that Nedd4-haploinsufficient mice fed a normal diet (ND) 
exhibited decreased body weight in both genders and proportionally reduced tissue mass 
compared to their age-matched wild-type littermates. The heterozygotic Nedd4-deficient 
mice displayed moderate insulin resistance and mild hyperinsulinemia. These findings 
are consistent with others’ studies in which depletion of Nedd4 in mouse embryonic 
fibroblasts (MEFs) led to a decline in insulin-like growth factor I (IGF-1) and insulin 
signaling.  
 
Surprisingly, Nedd4-haploinsufficient mice were partially protected against high-
fat diet (HFD) induced obesity. Total weight gain was decreased by 30% in Nedd4-
haploinsufficient mice on HFD, which was associated with reduced adiposity, improved 
insulin sensitivity in white adipose tissue (WAT), alleviated hepatic steatosis and 
attenuated lipid-induced inflammation. NEDD4 reduction did not affect serum glucose or 
lipid profile. The energy intake and physical activity were almost indistinguishable 
between the two groups. We present data indicating that these beneficial effects of Nedd4 
haploinsufficiency under conditions promoting obesity or type 2 diabetes (T2D) derive 
from at least two mechanisms: 1) elevated levels of ?-agonist induced lipolysis through 
stimulation of ?-adrenergic signaling as evidenced by enhanced ?? adrenergic receptor 
??2-AR) cell surface levels; 2) repressed expression of a key adipogenic regulator, 
peroxisome proliferator-activated receptor gamma (PPAR?) in Nedd4-haploinsufficient 
mice in the WAT. Downregulation of NEDD4 in 3T3-L1 preadipocytes impaired the 
adipogenic response, resulting in decreased PPAR? expression. Thus, the reduced 
adiposity in Nedd4-haploinsufficient mice fed a HFD compared to littermate wild-type 
mice may be explained at least in part by their increased lipolysis and suppressed 
adipogenesis. Our data also imply that NEDD4 may have differential functions in 
modulating insulin signaling under physiological and pathological conditions. 
 
In this study, we tested the possible impact of NEDD4 reduction on cognitive 
function and anxiety behaviors. Preliminary results showed that Nedd4-haploinsufficient 
mice had impaired learning and memory performance but increased anxiety compared to 
wild-type littermates. NEDD4 may modulate different behavioral functions by targeting 
specific substrates for protein degradation in a brain-region-specific manner. Precise 
substrates that cause the alteration in such behaviors are yet to be determined by future 
studies.  
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 CHAPTER 1.    INTRODUCTION 
 
 
1.1 Obesity 
 
 
1.1.1   Facts 
 
The World Health Organization (WHO) defines overweight and obesity as a state 
of “abnormal or excessive fat accumulation” (WHO official website). According to the 
statistics provided by the WHO, there are 500 million adults worldwide who are obese 
with a body mass index (BMI) over 30 kg/m2 and one billion who are overweight with a 
BMI over 25 kg/m2. The number of overweight children under the age of five is 
escalating each year exceeding 40 million in 2012 (Ogden et al., 2012). A survey 
conducted by the United States Centers for Disease Control and Prevention (USCDC) 
shows that Tennessee is among the states with highest obesity incident rate, having a 
prevalence greater than 30% (2008) .  
 
 Increasingly recognized as disorders in their own right, being overweight or obese 
certainly adversely affects individual’s quality of life. Moreover, an emerging body of 
scientific, medical, and behavioral studies suggest raised body fat as a major risk factor 
for the development of metabolic syndrome, T2D, cardiovascular disease (mainly heart 
disease and stroke), and certain types of cancer. In the United States alone, obesity and its 
complications contribute to over 300,000 premature deaths each year, making it the 
second preventable cause of death behind tobacco smoking (Mokdad et al., 2004). 
 
 
1.1.2   Etiology 
 
Causes of obesity include genetic predisposition, environmental and 
psychological factors. However, ultimately, obesity is a consequence of chronic 
imbalance between energy intake and output. In certain cases, energy required for growth 
and energy utilized for basic metabolic processes also account for the energy balance. 
When energy intake exceeds energy output, a state of positive energy balance occurs, 
thereby increasing body weight (Hill et al., 2012). After linear growth in early adulthood 
energy balance becomes determined by three basic components: energy intake, energy 
output, and energy storage (Hill et al., 2003). 
 
Humans absorb energy in the forms of protein, carbohydrate and fat. Humans 
expend energy primarily through basal metabolic rate, physical activity, and diet-induced 
thermogenesis. The basal metabolic rate is the rate of energy expenditure at rest, which is 
proportional to body mass and depends essentially on the lean mass (mostly the muscles) 
(White and Seymour, 2003). The basal metabolic rate represents 60-70% of the total 
energy output (Blundell et al., 2012). The energy expended through physical activity 
varies and accounts for 20-30% of total energy output (Rising et al., 1994). Diet-induced 
1 
 thermogenesis is an increase in metabolic rate that occurs after eating, representing 
approximately 10% of the total energy output (Tappy et al., 1991). 
 
 
1.1.2.1 Genetic Factors. Genetic factors may cause changes in energy intake. For 
example, mutations in leptin (Montague et al., 1997; Strobel et al., 1998), its receptor 
(Clement et al., 1998), or mutations in melanocortin receptor 4 (Vaisse et al., 1998; Yeo 
et al., 1998), proopiomelanocortin (Krude et al., 1998) and prohormone convertase 1 
(Jackson et al., 1997) lead to pronounced hyperphagia and obesity. Energy expenditure 
and energy storage can be regulated by genetic factors as well. For example, mutations in 
uncoupling protein-2 (Fleury et al., 1997), acyl CoA:diacylglycerol transferase (Smith et 
al., 2000), perilipin (Martinez-Botas et al., 2000), or cell death activator (cidea) (Zhou et 
al., 2003) can lead to corresponding metabolic modifications. Recent genome wide 
association studies and bioinformatics analysis have identified numerous single 
nucleotide polymorphisms (SNPs) and loci which are strongly associated with body 
fatness. Many of these SNPs lay within introns or even in the noncoding regions. Though 
many monogenic effects have been identified, multiple subtle variants in genes are likely 
to contribute to the common forms of human obesity, as is the case with T2D (Farooqi 
and O'Rahilly, 2007). 
 
 
1.1.2.2 Environmental Factors. Contemporary environments are filled with 
readily available, inexpensive foods with high calorie content facilitating obesity. 
Advanced technology and transportation systems promote sedentary life styles which are 
frequently linked to the epidemic of obesity (Hill and Peters, 1998).  
 
 
1.1.2.3 Psychological Factors. Obesity can be caused by psychological factors as 
well. People with psychological disorders (e.g. depression, anxiety, low self-esteem, or 
other emotions) may eat aberrantly, exercise insufficiently, and therefore, are more likely 
to develop obesity (Stice et al., 2005). 
 
 
1.1.3   Treatments 
 
Balanced eating and healthy lifestyle are important strategies for weight loss and 
maintenance. Weight loss helps improve overall health and reduce risk of developing 
cardiovascular complications. For treatment of obesity, the commercially available drugs 
mainly act through two mechanisms: reduce fat absorption through inhibition of gastric 
and pancreatic lipases (e.g. orlistat (Curran and Scott, 2004)) and suppress appetite (e.g. 
phentermine/ topiramate and lorcaserin (Fleming et al., 2013)).  
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 1.2 Adipose Tissue and Obesity 
 
Adipose tissue is the main storage site for excess energy in the form of 
triglycerides (TGs). Besides its storage function, adipose tissue also serves as an 
endocrine organ, which is able to secrete a variety of cytokines, including leptin. Adipose 
tissue is emerging as an important component in metabolism. An adipocentric view even 
considers adipose as a determinant factor for insulin resistance. Indeed, excessive adipose 
tissue increases the risk for the development of insulin resistance. Surprisingly, a lack of 
adipose tissue in the body, for example in the case of Berardinelli-Seip congenital 
lipodystrophy, in which fats are stored at ectopic sites in the body, such as in the liver and 
muscles, can also lead to severe insulin resistance (Magre et al., 2001). A transgenic 
model of inducible lipoatrophy provides consistent evidence (Pajvani et al., 2005).While 
these observations seem paradoxical at first sight, they imply that proper function of 
adipose tissue is critical for maintaining whole-body insulin sensitivity. A brief 
introduction to the concepts of insulin action and insulin resistance is necessary in order 
to understand these observations. 
 
 
1.2.1   Insulin Action in Adipose Tissue 
 
Insulin is a small molecule of 51-residue and with a molecular weight of 
approximately 6 kilodalton (kDa). It is produced by the pancreatic ???????, when amino 
acids or glucose levels are increased in the bloodstream. Tissues that are responsive to 
insulin action are referred to as insulin-sensitive tissues, which include but are not limited 
to skeletal muscle, liver, fat and hypothalamus.  
 
The cellular insulin signaling event initiates from the membrane-localized insulin 
receptor (IR), which belongs to the family of receptor tyrosine kinases (RTKs). The IR is 
????????????????????????????????????-??????????????????-subunits held together by 
disulfide and noncovalent bonds (Lee and Pilch, 1994). IR undergoes glycosylation 
before its insertion to the plasma membrane. Both subunits are exposed to the 
extracellular environment, while only the C-terminal ?-subunit is intracellular (Lee and 
Pilch, 1994). Following ligand binding, the ?-subunit undergoes autophosphorylation on 
seven Tyr residues in a sequential order and a conformational change that further 
increases kinase activity. The three most critical tyrosine sites are Tyr 1158, 1162 and 
1163, phosphorylation of which results in activation of the receptor kinase activity 
(Feener et al., 1993; Hubbard, 1997). Subsequently, the activated IR phosphorylates a 
number of intracellular substrates on tyrosine. The primary substrates are the members of 
the insulin receptor substrate family (IRS1/2/3/4). Other substrates include: Src-
homology-2-containing protein (Shc), IRS-5 and IRS-6 (or DOK-4 and DOK-5), Cas-Br-
M (murine) ectopic retroviral transforming sequence homologue (Cbl), Cbl-associated 
protein (CAP), signal transducer and activator of transcription (STAT) and GRB2-
associated-binding protein 1 (Gab-1), and p62dok (Cai et al., 2003; Lehr et al., 2000; 
Taniguchi et al., 2006; Wick et al., 2001).  
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 Following phosphorylation, these substrates serve as important intermediates that 
interact with other intracellular molecules. For example, tyrosine phosphorylation of IRS 
proteins creates recognition sites for other proteins containing Src homology 2 (SH2) 
domains, most notably, the p85 regulatory subunit of the phosphatidylinositol 3–kinase 
(PI3K) which activates AKT/protein kinase B (PKB) by catalyzing the production of 
phosphatidylinositol-3,4,5-triphosphate (PIP3) from phosphatidylinositol 4,5-
bisphosphate (PIP2) at the plasma membrane (Taniguchi et al., 2006). This eventually 
promotes the two main downstream signaling pathways: the PI3K-AKT/PKB pathway 
and the Ras–mitogen-activated protein kinase (Ras-MAPK) pathway. The former 
pathway mediates most of insulin's metabolic actions, while the latter pathway regulates 
general gene expressions for cell growth, survival, and differentiation (Taniguchi et al., 
2006).  
 
PI3K is necessary for insulin-stimulated glucose transport via AKT/PKB (Wang 
et al., 1999b) and/or the atypical protein kinase C (PKC) ???????????(Kotani et al., 1998), 
whereas another pathway involving the Cbl-CAP complex is also implicated for the 
translocation of glucose transporter type 4 (GLUT4) protein from intracellular sites to the 
cell surface of the membrane (Chiang et al., 2001).Besides stimulation of glucose uptake, 
insulin is also known to be an important antilipolytic hormone in adipose tissue. Insulin 
exerts its antilipolytic effect through inducing phosphorylation and activation of the 
phosphodiesterase type 3B (PDE3B), which is dependent on the activation of PI3K/AKT 
pathway (Kitamura et al., 1999; Rondinone et al., 2000). Activation of PDE3B decreases 
concentrations of adenosine 3’,5’-monophosphate (cAMP), which in turn reduces the 
activity of protein kinase A (PKA), a cAMP-dependent protein kinase (Degerman et al., 
1997). PKA is responsible for activation of two important proteins with established 
function in lipolysis: the hormone-sensitive lipase (HSL), an enzyme that catabolizes TGs 
in adipocytes, and perilipin A, a protein that associates with the surface of lipid droplets 
and the phosphorylation of which is required for lipid droplet mobilization (Zimmermann 
et al., 2004). It should be noted those insulin concentrations required for its antilipolytic 
effect are lower than that required for its glucose uptake effect. Hence, even under insulin 
resistant conditions when the insulin-stimulated glucose uptake is impaired, its 
antilipolytic effect maintains the growth of adipose tissue (Kahn and Flier, 2000). In 
addition, insulin serves as a potent pro-adipogenic hormone that triggers the expression 
of a series of transcription factors facilitating the conversion from pre-adipocytes to 
mature adipocytes (Rosen and MacDougald, 2006).  
 
 
1.2.2   Insulin Resistance in Adipose Tissue 
 
Insulin resistance is a physiological state where the body fails to respond 
adequately to insulin. This is manifested by reduced glucose uptake in adipocytes and 
skeletal muscle and by diminished suppression of hepatic glucose production. In the 
1930s, Dr. H.P. Himsworth was the first to distinguish insulin resistance from insulin 
deficiency (Himsworth, 1940). He found that some diabetic individuals (typically lean 
and with early-onset diabetes) could rapidly respond to the injection of insulin, while 
some others (obese and with later-onset diabetes) could not. Following this track, in the 
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 1960s, Dr. D. Rabinowitz and K.L. Zierler discovered that some obese but non-diabetic 
individuals were also resistant to the effects of insulin (Rabinowitz and Zierler, 1961). An 
extensive clinical study in 1990s provided the most direct evidence that the insulin 
sensitivity index is negatively correlated with abdominal fatness in both men and women 
(Clausen et al., 1996). Normally, the more fat tissue one has the more resistant his or her 
cells respond to insulin. Therefore, insulin resistance is commonly seen coexisting with 
obesity. It is now well accepted that obesity-associated insulin resistance is the major 
mechanistic basis for the link between obesity and many other metabolic diseases, such 
as T2D and cardiovascular disease (Kahn and Flier, 2000).  
 
Insulin resistance in obesity is hypothesized to be caused by defects at multiple 
levels of insulin signaling, increased amount of non-esterified fatty acids (NEFAs), also 
referred to as free fatty acids (FFAs), released from adipose tissue and changed adipokine 
profile. 
 
 
1.2.2.1 Defects in Insulin Signaling. Several lines of evidence suggest that 
insulin signaling in insulin-responsive tissues is impaired in obesity. In skeletal muscles 
from obese humans, expression of several insulin signaling molecules was decreased 
(Goodyear et al., 1995). In obese humans with T2D, IRS-1 expression was found to be 
reduced in adipocytes (Rondinone et al., 1997), and PI3K activity was attenuated in both 
adipocytes and skeletal muscles (Kim et al., 1999; Rondinone et al., 1997). Mice double 
knockouts of IRS-1 and IRS-3 exhibited a severe phenotype: severe lipoatrophy at early 
stage and insulin resistance (Laustsen et al., 2002). The expression and activity of several 
protein tyrosine phosphatases (PTPs), such as PTP1B and src-homology-containing-
phosphatase 2 (SHP-2) were increased in skeletal muscle and adipose tissue in obese 
humans and rodents (Goldstein et al., 1998). PTPs are negative regulators of insulin 
signaling by dephosphorylating IR. In agreement, PTP1B knockout mice had increased 
insulin sensitivity and resistance to diet-induced obesity (Elchebly et al., 1999; Klaman et 
al., 2000).  
 
Surprisingly, the fat insulin receptor knockout (FIRKO) mice displayed improved 
metabolic outcomes compared to wild-type mice (Bluher et al., 2002). When the mice 
were fed with a high-fat diet (HFD) or were treated with gold thioglucose, which caused 
hypothalamic damage and hyperphagia, the beneficial effects of the loss of insulin 
signaling in fat became even more significant. The FIRKO mice had reduced fat mass. 
They were protected against obesity and its associated glucose intolerance (Bluher et al., 
2003; Bluher et al., 2002). Moreover, both male and female FIRKO mice had an increase 
in average life-spans (Bluher et al., 2003). Therefore, reduced insulin signaling in 
adipocytes, nonetheless, appears to prevent the development of obesity and its associated 
metabolic abnormalities. 
 
 
1.2.2.2 Increased Release of FFAs. Elevated FFA concentrations in obesity are 
thought to arise from the expanded adipose tissue. FFA has long been recognized as an 
energy source for other tissues. An additional function of FFA as an endocrine factor that 
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 regulates metabolic functions has been proposed since 1960s (Kennedy, 1992).Moreover, 
FFA has been proposed as a major culprit for insulin resistance: under insulin resistant 
state, lipolysis in adipocyte which is normally suppressed by insulin, is further increased, 
thereby liberating more FFA and in turn aggravating insulin resistance. In this model, 
elevated FFA levels are demonstrated to lead to intracellular accumulation of several 
metabolites including acyl-CoAs, ceramides, and diacyglycerol (DAG), which can 
activate protein kinases such as PKC, c-Jun N-terminal kinases (JNKs), and the inhibitor 
of nuclear factor-??????-??????????-??????????????????nases in turn increases the 
inhibitory serine phosphorylation of IRS1/2 (Petersen and Shulman, 2006). 
 
However, this concept has now been questioned. In a clinical study involving a 
prospective cohort of 481 women and 345 men, the fasting FFA concentrations did not 
predict the development of insulin resistance (Byrne et al., 1999). In the Karpe et al. 
study, in which 43 original reports including a total number of 953 non-obese (control) 
patients and 1,410 overweight/obese patients were pooled and reanalyzed in aggregates 
by literature search from PubMed and were aligned for a relationship between the fasting 
FFA concentration and the fat mass. Surprisingly, the result clearly showed a complete 
absence of relationship between adipose tissue mass and the fasting FFA concentration 
(Karpe et al., 2011). Therefore, whether the elevated FFA levels truly contribute to the 
pathogenesis of obesity-associated insulin resistance remains an open question. 
 
 
1.2.2.3 Changed Adipokine Profile. The profile of adipokines secreted from 
adipose tissue also undergoes major changes in obesity. Release of most adipokines is 
elevated in obesity, including the metabolically beneficial hormone leptin (Sinha et al., 
1996). Leptin signaling is concomitantly impaired in obesity(Jequier, 2002). Loss of 
leptin produced severe obesity in a previous study (Montague et al., 1997). Resistin, an 
adipocyte-secreted protein, was also found to circulate at high levels in the bloodstream 
in obese rodents. Infusion or sustained overexpression of resistin caused insulin 
resistance, while knocking out resistin in mice improved glucose metabolism (Steppan et 
al., 2001). Conversely, adiponectin levels are low in obesity. The administration or 
transgenic overexpression of adiponectin improved insulin resistance and lowered FFAs 
in serum in animal models (Lihn et al., 2005). Consistently, adiponectin-deficient mice 
developed insulin resistance and had increased serum FFAs (Lihn et al., 2005). 
 
Highly upregulated adipokines in adipose tissue of obese subjects also include 
several proinflammatory cytokines. For example, the plasma concentration of monocyte 
chemoattractant protein 1 (MCP-1) was high in obese mouse models, leading to massive 
macrophage infiltration and insulin resistance (Kanda et al., 2006). Other inflammation-
associated cytokines released from macrophages or adipocytes are tumor necrosis factor 
? (????), interleukin-1? (IL-??) and interleukin-6 (IL-6) (Qatanani and Lazar, 2007). It 
has been proposed that cytokines released from adipose tissue induce a systemic low-
grade inflammation and promote insulin resistance (Xu et al., 2003). 
 
 
6 
 1.2.3   Lipid Storage and Mobilization in Adipose Tissue 
 
Adipocytes synthesize TGs from circulating FFA pool. After a meal, circulating 
dietary fat absorbed by the intestinal tract in the form of chylomicrons is hydrolyzed by 
lipoprotein lipase (LPL) in the capillary endothelium in adipose tissue. FFAs thus 
released are taken up into the adipocytes for storage. The endogenous TGs carried by 
very low-density lipoprotein (VLDL) are removed by LPL from VLDL and taken up by 
adipocytes via VLDL receptor (VLDL-R) or low density lipoprotein receptor-related 
protein (LRP) for storage. FFAs can also be transported into adipocytes via a family of 
fatty acid transport proteins (FATPs), such as FATP1 (Gimeno, 2007). Fatty acids are 
transported by fatty acid binding proteins (FABPs) inside an adipocyte, notably the 
FABP-4 (Maeda et al., 2005). After their entry, fatty acids are esterified by acyl-coA 
synthetase. Esterified fatty acids together with glycerol are used for TG synthesis. 
Alternatively, adipocytes can use acetyl-CoA for de novo fatty acid synthesis via acetyl-
CoA carboxylase (ACC) and fatty acid synthase (FAS). TG are incorporated into lipid 
droplets and covered by perilipin. The remnant FFAs and TG-rich lipoproteins that are 
not taken up by the adipocytes are eventually taken up in ectopic sites, such as skeletal 
muscles, liver, pancreas, and heart (Karpe et al., 2011).  
 
FFAs are stored as TG in a highly dynamic fashion. When necessary, FFAs can 
be re-released from fat. Break down of TGs to glycerol and FFAs is called lipolysis. 
During energy deprivation (e.g. fasting and exercise), lipolysis is stimulated in adipocytes 
and leads to the liberation of FFAs, which can be metabolized by other tissues, such as 
muscle, for energy production via ?-oxidation (Duncan et al., 2007). The process of TG 
hydrolysis is three steps: TG is first to form diacylglycerol (DAG) by adipose triglyceride 
lipase (ATGL), then to monoacylglycerol (MAG) by HSL, and finally to FFAs and 
glycerol by monoacylglycerol lipase (MGL). HSL is the rate-limiting as well as the 
hormonally regulated step of this process. The lipolytic response is mainly controlled by 
catecholamines (epinephrine and norepinephrine) and the fasting hormones glucagon, via 
their binding to respective receptors, i.e. adrenergic receptors and glucagon receptors. 
Both lead to activation of adenylate cylase by stimulatory guanine nucleotide regulatory 
proteins (Gs) within the plasma membrane. Adenylate cyclase then enzymatically 
converts ATP to cAMP, which in turn activates PKA by binding to its regulatory subunit 
and releasing its catalytic subunit. Subsequently, the catalytic subunit of PKA 
phosphorylates perilipin and HSL for fat mobilization (Figure 1.1). While fasting or 
exercise enhance lipolysis, defective lipolysis was found in mature fat cells and in 
differentiated preadipocytes isolated from obese and non-obese human (Langin et al., 
2005). Therefore, modulation of adipocyte lipolysis via pharmacological intervention 
may be a promising therapeutic strategy for treating obesity. 
 
 
1.2.4   Different Adipose Tissue Depots 
 
Classically, there are two types of adipose tissues within body: white and brown. 
It has long been believed that only newborns humans and rodents have interscapular 
brown adipose tissue (BAT). However, several recent studies show that brown adipocytes  
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 Figure 1.1   ?????? ???????????????????????????-adrenergic and Insulin Signaling. 
Adipocyte ???????????????????-AR subtypes—?1???2, and ?3. Catecholamine binds to the ?-
AR and initiates a dissociation of G?s from G??. G?s stimulates the membrane 
associated enzyme adenylate cyclase (AC) to promote the production of cAMP from ATP 
and subsequently, activates PKA. Activated PKA phosphorylates both perilipin-1 and 
HSL. Phosphorylated perilipin-1 releases 1-acylglycerol-3-phosphate O-acyltransferase 
(ABHD5) (or CGI-58) to ATGL. Upon ABHD5 binding, ATGL is activated and initiates 
lipolysis of TG to produce DAG and FFA. PKA-activated HSL further hydrolyzes DAG 
to MAG and FFA. MAG is finally hydrolyzed to glycerol and FFA by MGL. Glycerol 
and FFA can be transported outside of the adipocyte by their respective transporter 
proteins, while FFA can also diffuse through plasma membrane. Insulin binding to IR on 
the surface of adipocyte activates PDE through PI3K/AKT pathway. PDE inhibits the 
production of cAMP and consequently reduces the activity of PKA. On the other hand, 
insulin promotes the translocation of GLUT4 to cell membrane and facilitates glucose 
uptake into adipocyte which is converted to glycerol-3-phosphate (G3P) through 
glycolysis. Insulin also activates LPL on adipocyte surface. Activated LPL releases FFA 
from lipoprotein which is subsequently transported or diffuses into adipocyte. 
Intracellularly, FFA is converted to acyl-CoA. G3P and acyl-CoA serves as substrates for 
synthesis of TG at ER. PA, phosphatidic acid; LPA, lysophosphatidic acid. 
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 also exist in adult humans and are interspersed into the white adipose tissue (WAT) 
(Giralt and Villarroya, 2013). But these brown adipocytes are different from the classical 
brown adipocytes and share many similarities with the white adipocytes cell linage, and 
therefore, sometimes are referred to as the “inducible, beige, brite” adipocytes (Giralt and 
Villarroya, 2013). White adipocytes contain a single lipid droplet, while brown 
adipocytes contain multilocular droplets and higher density of mitochondria. BAT can be 
induced by cold or exercise (Cannon and Nedergaard, 2004), and primarily function to 
promote non-shivering thermogenesis. Inducible thermogenic genes in BAT genes 
include: uncoupling protein 1 (UCP1), PRD1-BF-1-RIZ1 homologous domain containing 
protein-16 (PRDM16), peroxisome proliferator-activated receptor gamma (PPAR?) 
coactivator 1-alpha (PGC-1?), PGC-1?, and CIDEA (Kajimura et al., 2010). 
 
WAT represents the majority of body fat. WAT can be further classified by its 
location into subcutaneous adipose tissue which is underneath the skin and visceral (or 
abdominal) adipose tissue which is located inside the abdominal cavity. Mesenteric, 
epididymal white adipose tissue and perirenal depots all belong to visceral adipose tissue. 
Although subcutaneous and visceral adipose tissues are both WAT, they are distinct in 
terms of functional implications. For example, enlargement of visceral WAT is more 
associated with metabolic syndrome than that of subcutaneous WAT (Ibrahim, 2010). 
Visceral adipose tissue is also richer in blood and more innervated (Ibrahim, 2010). In 
addition, visceral adipocytes are more metabolically active, hormonally responsive to 
adrenergic-stimulated lipolysis than subcutaneous adipocytes (Arner, 1995; Arner et al., 
1990; Hellmer et al., 1992).  
 
 
1.2.5   Hypertrophy and Hyperplasia of Adipose Tissue 
 
Adipose tissue expands in obesity to store excess energy. As excess energy 
accumulation within the body continues, adipocytes will expand in size (hypertrophy) 
and/or increase in number (hyperplasia) to store more lipids. Hyperplastic growth is 
found solely at early stages of adipose tissue development in human and the adipocyte 
number become stable in adulthood (Spalding et al., 2008). In rodents, both size and 
number of adipocyte can change along development of obesity, with the observation that 
hypertrophy occurs prior to hyperplasia (Faust et al., 1978). Although it seems feasible to 
combat obesity by restricting adipose tissue expansion, as hypertrophy and hyperplasia 
are known to facilitate obesity, modulating transcription factors to inhibit adipocyte 
development and adipose tissue expansion concomitantly affects metabolic homeostasis 
(Stephens, 2012). 
 
The dominant cell type within adipose tissue is mature adipocytes. Nonetheless, 
endothelial cells, vascular smooth muscle cells, immune cells such as macrophages as 
well as fibroblasts can also be found in the adipose tissue. In addition, adipocyte 
precursor cells coexist within adipose tissue, which can be regenerated into mature 
adipocytes through a process called adipogenesis.  
 
 
10 
 Several immortalized cellular models can be used to study adipogenesis, such as 
the 3T3-L1 and 3T3-F442A cell lines derived from Swiss mouse embryos, embryonic 
stem cells, primary mouse embryonic fibroblasts (MEFs), immortalized MEFs, 
immortalized brown-adipose stromal cells, and immortalized multipotent precursor cells. 
Nonetheless, the methodologies used to differentiate these cells may be different. The 
3T3-L1 and 3T3-F442A cell lines could be differentiated to mature adipocytes when 
treated with a hormonal cocktail, whereas the differentiation of immortalized MEFs 
requires the overexpression of a pro-adipogenic transcription factor such as ????? or 
CCAAT-enhancer- binding protein alpha (C/EBP?) (Rosen and MacDougald, 2006).  
 
One of the major adipogenic regulators is the transcription factor ?????, which 
is both necessary and sufficient for adipogenesis (Rosen et al., 2000). Other transcription 
factors that facilitate adipogenesis include members of the C/EBP family, members of the 
Krüppel-like factors (KLFs) family of proteins, STATs, and SREBP-1 (Sarjeant and 
Stephens, 2012). However, ?????????????????and/or activity are likely required for the 
action of most of the pro-adipogenic factors (Rosen and MacDougald, 2006). Negative 
transcription factors for adipogenesis include the surface protein preadipocyte factor1 
(PREF1) and members of the GATA family, which function in part ????????????????????
expression (Tong et al., 2000). These pro- and anti- adipogenic factors often work in 
complex with co-activators or co-repressors. The most well-studied anti-adipogenic 
nuclear receptor co-repressor is NcoR (Li et al., 2011). PPAR? has two protein isoforms 
that are generated by alternative splicing, i.e. PPAR?1 and PPAR?2. While these two 
proteins are induced during adipogenesis, their relative importance remains elusive. 
????????? believed to be more efficient in promoting adipogenesis than the other 
isoform PPAR?1, but is not necessarily required for adipocyte development in vivo 
(Mueller et al., 2002; Zhang et al., 2004).  
 
 
1.3 NEDD4 
 
 
1.3.1   E3 Ligases in Metabolism 
 
The conjugation of ubiquitin to a protein substrate is a three-step process. In the 
first step, the C-terminus of ubiquitin binds a Cys residue within a ubiquitin-activating 
enzyme (E1) by forming a thioester bond. E1 enzyme activates the ubiquitin and transfers 
it to a specific Cys residue within a ubiquitin-conjugating enzymes (E2s). E2s can then 
transfer ubiquitin directly to substrates when working with RING (Really Interesting 
New Gene) domain ubiquitin-protein ligases (E3s), or through specific HECT E3s. N-
terminus of ubiquitin is thus linked to specific internal Lys residues of target proteins. 
Substrates can undergo monoubiquitylation, multi-ubiquitylation or polyubiquitylation. 
Polyubiquitylated proteins are normally degraded by the 26S proteasome (Rotin and 
Kumar, 2009). Besides its most notable proteolytic function, ubiquitination also regulates 
receptor internalization, protein lysosomal sorting, interaction, subcellular distribution, 
and gene transcription, etc. (Chen and Sun, 2009).  
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 In recent years, several E3 ligases have been reported to be implicated in the 
regulation of body metabolism. For example, the Casitas B-lineage lymphoma (Cbl) 
homologue, Cbl-b, which belongs to the RING-type E3 ligase has been reported to 
regulate obesity and macrophage activation. In a report by Hirasaka et al., Cbl-b-/- mice 
displayed enhanced insulin resistance and macrophage activation in adipose tissue 
(Hirasaka et al., 2007). A similar conclusion was reached in Abe et al.’s study: Cbl-b 
deficiency enhanced saturated FFA-induced macrophage activation and exaggerated 
HFD-associated insulin resistance (Abe et al., 2013). Depletion of another Cbl 
homologue, c-Cbl, reduced adiposity, improved insulin sensitivity (Molero et al., 2004) 
and protected mice against HFD-induced obesity (Molero et al., 2006). Other examples 
are the muscle-specific mitsugumin 53 (MG53, also known as TRIM72) and cullin-7 
(CUL7), two RING-type E3 ligases which mediated IRS-1 ubiquitination and 
degradation, and therefore, negatively modulated insulin signaling (Lee et al., 2010; Xu 
et al., 2008; Yi et al., 2013). Loss and overexpression of MG53, protected against and 
triggered insulin resistance and metabolic syndrome in mice under HFD challenge (Song 
et al., 2013). Depletion of ITCH, a HECT-type E3 ligase involved in T-cell 
differentiation and inflammatory regulation, reversed HFD-induced obesity, the 
associated insulin resistance and liver steatosis (Marino et al., 2014). The beneficial 
effects of ITCH loss of function were likely due to the accelerated metabolism and 
increased differentiation of M2 macrophages, as well as the enhanced fatty acid oxidation 
in Itch-deficient mice (Marino et al., 2014). Consistently, in human adipose tissue, 
expression of ITCH was negatively correlated with that of the M2 macrophage markers 
(Marino et al., 2014).  
 
 
1.3.2   NEDD4 and Its Substrates 
 
Neural precursor cell expressed, developmentally down-regulated 4 (NEDD4) is a 
HECT-type E3 ubiquitin ligase, which was first identified from a screen for 
developmentally regulated gene in early embryonic mouse central nervous system (CNS) 
in 1997 (Kumar et al., 1997). NEDD4 is believed to be the ancestral member of the 9-
membered NEDD4 family (Yang and Kumar, 2010). Mouse and rat NEDD4 are almost 
identical with only two amino acids difference. However, human NEDD4 has 5 splice 
variants ranging from 900 to 1302 amino acid in length. NEDD4 contains an N-terminal 
C2 domain for calcium/lipid and/or protein binding, 3 to 4 WW domains for protein–
protein interaction, and a C-terminal catalytic ligase domain (HECT domain). WW 
domains is the main component determining the substrates binding by NEDD4 via 
binding PPxY (PY) or LPSY motifs, although the C2 domain of NEDD4 also bind 
substrates (Yang and Kumar, 2010).  
 
Despite the fact that many studies support NEDD4 as a critical player in early 
embryonic development (Cao et al., 2008; Fouladkou et al., 2010; Liu et al., 2009), 
knowledge toward the patho-physiological functions of this protein in postnatal life is 
limited. Recent experimental results indicate that NEDD4 plays a pivotal role in 
regulating receptor signaling by regulating receptor endocytosis (Rotin et al., 2000), A 
partial list of substrates of NEDD4 includes: epidermal growth factor receptor (EGFR) 
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 (Lin et al., 2010), vascular endothelial growth factor receptor 2 (VEGF-R2) (Murdaca et 
al., 2004), insulin-like growth factor receptor type 1 (IGF-1R) (Vecchione et al., 2003), 
IR (Ramos et al., 2006), Notch1 (Koncarevic et al., 2007), PTEN (Wang et al., 2007), 
beta-2 adrenergic receptor (?2-AR) (Nabhan et al., 2010; Shenoy et al., 2008), fibroblast 
growth factor receptor (FGFR1) (Persaud et al., 2011), AKT (Fan et al., 2013), and Ras 
(Zeng et al., 2014). Since most of these substrates of NEDD4 are active players in various 
metabolic pathways, hence, we hypothesized that NEDD4 could be a new player in the 
regulation of metabolism. 
 
 
1.3.2.1 IGR-1R and IR. In several cell-based studies, NEDD4 was found in 
complex with growth factor bound-receptor 10 (Grb10) to mediate ligand-stimulated IR 
and IGF-1R ubiquitination, which subsequently facilitated their internalization and/or 
degradation (Monami et al., 2008; Ramos et al., 2006; Vecchione et al., 2003). Reduction 
in NEDD4 expression was presumed to stabilize IR and IGF-1R upon ligand stimulation, 
and thus potentiats insulin and IGF-1 signaling. However, more recent evidence from in 
vivo studies revealed that insulin/IGF-1 signaling in NEDD4 knockout embryos were 
reduced, suggesting a more complex role of NEDD4 in vivo. Mice homozygous for 
targeted mutation of the Nedd4 gene died during or shortly after birth and exhibited 
severe intrauterine growth retardation (body weight of Nedd4-/- embryos and newborn 
pups were only 35% of normal) (Cao et al., 2008; Liu et al., 2009). The growth 
deficiency in Nedd4-haploinsufficient mice are similar in severity to the previously 
characterized mice carrying an Igf1r null mutation (45% of normal birth weight) (Baker 
et al., 1993; Liu et al., 1993), suggesting an impaired IGF-1 signaling in the absence of 
NEDD4 during embryogenesis. Indeed, in cultured Nedd4-/- MEFs, cell surface 
expression of both IGF-IR and IR were found to be substantially reduced (Cao et al., 
2008). Additionally, the authors speculated that reduction in insulin and IGF-1 signaling 
by NEDD4 depletion is likely through increased expression of Grb10 (Cao et al., 2008), a 
known negative regulator for IR and IGF-1R function. The level of Grb10 was elevated 
in NEDD4 knockout MEFs, which may in turn impede insulin/IGF-1 signaling. The 
lethality of NEDD4 knockout mice could be partially rescued by crossbreeding with 
Grb10-deficient mice (Cao et al., 2008). Since Grb10 also binds IR (Liu and Roth, 1995) 
which shares structural and downstream signaling similarities with IGF-1R, it is possible 
that NEDD4 also regulates insulin signaling via elevated Grb10; Grb10 associates 
preferentially with IR as compared with IGF-1R (Laviola et al., 1997).  
 
 
1.3.2.2 ?2-AR. Agonist treatment for different length of time resulted in different 
effects on ?2-AR trafficking. Short exposure within 1 hr caused internalization of the 
phosphorylated receptor which were recycled to the membrane after dephosphorylation; 
prolonged exposure from hours to days caused receptor protein degradation (Shenoy et 
al., 2001). NEDD4 has been demonstrated to be an essential E3 ligase mediating agonist-
stimulated ubiquitination and degradation of ?2-AR (Nabhan et al., 2010; Shenoy et al., 
2008). In Shenoy et al.’s study, expression of a dominant negative NEDD4 or siRNA 
targeting NEDD4 specifically inhibited isoproterenol-induced ubiquitination and 
degradation of the ?2-AR in HEK-293 cells, whereas other closely related E3 ligases had 
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 no effects (Shenoy et al., 2008). Moreover, the interaction between NEDD4 and ?2-AR 
was ablated by an siRNA targeting arrestin beta 2 (?-arrestin2), suggesting an adaptor 
role for ?-arrestin2 in the interaction (Shenoy et al., 2008). In Nabhans et al.’s study, an 
alpha arrestin, arrestin domain-containing 3 (ARRDC3), was found to be involved in ?2-
AR downregulation as revealed by a genome-wide RNA interference screen using a cell 
line that expressed ??????????????????????????????2-AR (?2-ARt) (Nabhan et al., 2010), as 
the ?2-ARt underwent faster receptor degradation upon agonist stimulation than the wild-
type receptor (Cao et al., 1999). Interestingly, they found that ARRDC3 also served as an 
adaptor protein that regulated ?2-AR via recruiting the E3 ligase NEDD4 (Nabhan et al., 
2010) (Figure 1.2). In support of these in vitro observations, in vivo evidence collected 
by another group of researchers showed that the Arrdc3-deficient mice were resistant to 
age-induced obesity (Patwari et al., 2011). The Arrdc3-deficient mice exhibited enhanced 
energy expenditure with increased thermogenesis in both BAT and WAT, and enhanced 
cAMP accumulation and lipolysis in response to norepinephrine (Patwari et al., 2011), 
suggesting increased ?-AR signaling in vivo when the interaction between NEDD4 and 
?2-AR was abrogated. 
 
 
1.4 Summary 
 
The HECT-type E3 ubiquitin ligase NEDD4 has a large number of substrates that 
are active players in the growth factor receptor signaling, implying a potential role of 
NEDD4 itself in regulating whole-body metabolism. Besides the receptors mentioned 
previously, PTEN (Kwak et al., 2010; Wang et al., 2007), AKT (Fan et al., 2013), and 
Ras (Zeng et al., 2014) are also demonstrated to be the substrates of NEDD4 in different 
context. To investigate the function of NEDD4 in metabolic regulation in vivo, we 
characterized the metabolic phenotypes of Nedd4-haploinsufficient mice in a diet-
induced obesity (DIO) model, due to the fact that homozygous Nedd4 deletion causes 
embryonic/perinatal lethality. In this study, we also tested the possible impact of NEDD4 
reduction on cognitive function and anxiety behaviors, as NEDD4 is highly expressed in 
the brain and regulates several growth factor receptor signaling pathways involved in 
CNS development and function. 
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Figure 1.2   ???????????????2-AR Endocytosis and Degradation by NEDD4. 
Ligand binding induces phosphorylation within ?2-AR and the recruitment of ?- or ?-
arrestins to the receptor. The ?- or ?-arrestins serve as the binding sites for the WW 
domains of NEDD4, therefore bringing NEDD4 in proximity to ?2-AR. The HECT 
domain within NEDD4 catalyzes ubiquitination of ?2-AR serving as a signal for receptor 
endocytosis and subsequent degradation. 
  
15 
 CHAPTER 2.    MATERIALS AND METHODS 
 
 
2.1 Animal Studies 
 
The Nedd4-haploinsufficient mice (Nedd4Gt(OST16211)Lex) were originally generated 
by Lexicon Genetic Incorporated and are stocked at the Mutant Mouse Regional 
Resource Center (MMRRC) (http://www.mmrrc.org/strains/11742/011742.html). All 
mice were kept on a 12/12 light/dark cycle with lights on at 6:00 AM in a pathogen-free 
animal facility. The animals had ad libitum access to water and food at all times. Food 
was only removed when required.  
 
 
2.1.1   Genotyping 
 
Tail tissue (2-5 mm) from young (< 21 days) mice was taken by a sterilized 
scissor. DNA was isolated by phenol-chloroform extraction. PCR was performed with 
GoTaq Flexi DNA Polymerase (Promega). Nedd4 mice were genotyped by PCR with the 
following primer sequences: Nedd4 wild type allele-forward GGA GTC TTT GGA TAT 
TGT AAG AGC; Nedd4 mutant allele-forward AAA TGG CGT TAC TTA AGC TG 
CTT GC; and a common reverse GAG CGT GCG CCT CAC AAG TAT GA.  
 
 
2.1.2   Food Intake, Body Weight, and Body Length Measurement 
 
Mice were fed either a normal control diet (8640, Teklad, Harlan Laboratories) 
with 17% of total calories from fat, 54% from carbohydrate and 29% from protein, or a 
HFD (TD.06414, Teklad, Harlan Laboratories) with 60.3% of total calories from fat,  
21.3% from carbohydrate and 18.4% from protein, starting from 6 weeks of age. The 
HFD is packed in the form of pellet and kept at 4°C until use. For food intake 
measurement, mice at 12-16 weeks of age were ad-libitum fed a known amount of food. 
After 24 hr, the remaining food pellets were weighed. The consumption of food (absolute 
food intake) was calculated by the difference. Animals’ food intake was monitored on a 
daily basis for a continuous 7-day period. Body weights were monitored on a weekly 
basis with a small scale. For body length measurement, mice between 12-16 weeks of age 
were anesthetized or euthanized. Then a ruler was hold up against the body to measure 
the length from nose to anus. 
 
 
2.1.3   Glucose Tolerance Test (GTT) and Insulin Tolerance Test (ITT) 
 
For GTT, mice fasted overnight were weighed. Glucose were intraperitoneally 
(i.p.) injected to the mice at a dose of 1.5 g/kg body weight. Blood glucose level was 
measured with a glucometer (OneTouch Ultra glucometer, LifeScan) in a drop of blood at 
time 0 (before the injection of glucose) and 30, 60, 90, 120, and 180 min after glucose 
injection. For ITT, mice were fasted for 4 hr and then i.p. injected with insulin at 0.75 
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 U/kg body weight. Blood glucose concentrations were read from a glucometer with a 
drop of blood at time 0 and 30, 60, and 90 min after insulin administration.  
 
 
2.1.4   Insulin Signaling 
 
For peripheral insulin signaling analysis, adult mice fasted overnight were i.p. 
injected with 5 U/kg of insulin diluted in normal saline or an equal volume of saline. 
Mice were euthanized 15 min after injection. Liver, gastrocnemius muscle, and 
epididymal WAT were dissected and immediately frozen in liquid nitrogen. For central 
insulin signaling analysis, P0 neonatal mice were euthanized by decapitation. The entire 
brains were carefully removed by opening the skull with a dissecting scissor. The isolated 
brains were placed in a clean tissue culture plate (100 mm) containing sterile Hank's 
Balanced Salt Solution (HBSS). Under a light microscope, the cerebellum was removed; 
then the thin and transparent layer which contains fibrous and vascular tissues 
surrounding the forebrain was gently removed by dissecting forceps. Tissues containing 
hypothalamus, amygdala, thalamus and striatum were carefully removed by dissecting 
forceps. Other non-cortical tissues were also carefully removed, leaving only a thin layer 
of cortical tissue. These cortical tissues were minced into pieces of relatively equal size 
with dissecting forceps and placed into different wells prefilled with 500 ?l of HBSS of a 
24-well plate. These tissues were then incubated with insulin at different doses or for 
different time (up to 60 min). Tissue lysates were subjected to Western-blot analysis.  
 
 
2.1.5   Measurement of Metabolites and Hormones 
 
Blood was collected through lateral saphenous vein. Briefly, the animal was 
secured in a restrainer. The rear leg was stretched out to its natural position. The hair was 
removed by a small shaver and swabbed using 70% ethanol. The vessel was punctured 
with a 25-26 gauge needle and blood was collected with a heparinized capillary tube. 
Blood glucose levels were measured using a glucometer as mentioned in GTT and ITT. 
After collection of blood, the blood was allowed to clot by leaving it undisturbed at room 
temperature (RT) for 30 min. Serum was obtained by centrifuging clotted blood in tubes 
at 1,600 g for 10 min at 4°C and stored at -80°C until use. Serum insulin levels were 
determined with murine ELISA kits (Crystal Chem). Total serum TGs, glycerol, 
cholesterol, and FFAs were assayed using enzymatic methods with a colorimetric or 
fluorometric assay kit (Cayman). Serum insulin levels during GTT were determined with 
a murine ELISA kits (Crystal Chem). 
 
 
2.1.6   Histology 
 
Mouse was cardiac-perfused first with phosphate buffered saline (PBS) to clear 
blood, then with 4% paraformaldehyde (PFA) for fixation. Epididymal adipose tissue and 
liver was dissected and post-fixed in 4% PFA for 24 hr. Adipose tissue was subjected to 
paraffin embedding and sectioning to 10 ???????????Liver was immersed in 30% sucrose 
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 prepared in PBS for dehydration, then embedded in optimum cutting temperature 
compound (OCT), and cryosectioned with a cryostat (Leica CM 1860).  
 
Hematoxylin and eosin (H&E) staining of sections was performed according to 
standard procedures (Fischer et al., 2008). Briefly, sections were stained with 
hematoxylin for nuclei, rinsed with running tap water, counterstained with eosin, and 
dehydrated before mounting. The paraffin embedded sections were dewaxed and 
rehydrated by sequentially immersing in xylene, ethanol, and water before H&E staining. 
Microscopic pictures were taken and adipocyte size was measured in 300-400 cells per 
mouse in randomly selected fields using ImageJ software (National Institutes of Health, 
Bethesda, Maryland; http://imagej.nih.gov/ij/). For Oil red O staining in liver, 
cryosections were air dried and fixed in 10% formalin. Sections were briefly washed with 
running tap water, immersed in 60% isopropanol for 5 min, and stained with freshly 
prepared oil red O working solution for 15 min. Then, sections were briefly 
counterstained for nuclei with hematoxylin, rinsed with distilled water and mounted with 
glycerine jelly. 
 
 
2.1.7   Lipolysis Assay 
 
During the in vivo lipolysis assay, the non-selective ?-agonist isoproterenol was 
i.p. injected into mice fasted overnight, at 10 mg/kg body weight. Blood samples were 
collected at time 0 and 10, 30, and 60 min after the injection. The ex vivo lipolysis assay 
was performed as described in (Qiao et al., 2011). During primary adipocyte lipolysis 
assay (Viswanadha and Londos, 2006, 2008), minced epididymal WAT was digested in a 
Krebs-Ringer bicarbonate (KRB) buffer (pH 7.4) plus 3% fatty acid-free BSA fraction V, 
0.5 mM adenosine, and 1 mg/mL type I collagenase at 37°C for 45 min. After digestion 
and three washes with KRB plus 3% fatty acid-free BSA, the dissociated adipocytes were 
counted with a hemocytometer under a microscope. Approximately 12,000 adipocytes 
were resuspended in 400 ?L KRB buffer plus 3% fatty acid-free BSA. Isoproterenol was 
then added to the buffer ???????????????? hr incubation at 37°C with gentle shaking, 
samples were centrifuged and the infranatant (media below the floating adipocyte layers) 
was removed and stored at -80°C before use. Glycerol levels were measured by using a 
colorimetric assay kit (Cayman) following the manual. 
 
 
2.1.8   Fear Conditioning 
 
Mouse was subjected to fear conditioning training on day 1, a context fear 
retrieval test and a tone fear retrieval test (at least 3 hr apart) on day 2. In the fear 
conditioning trial, mouse was gently placed in a chamber of 30 × 30 × 25 cm in 
dimension (Coulbourn Instruments). After a 3 min recording for baseline activity, two 
paired tone-shock stimuli were presented one minute apart. The paired tone-shock stimuli 
consisted of a 20 sec tone (2800 Hz, 82 dB) and a 2 sec electrical footshock (0.7 mA) at 
the distal end of the tone. One minute after the second tone-shock stimulus, mouse was 
returned to its home cage. During the context fear retrieval trial on day 2, mouse was 
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 placed back to the same chamber for a 3 min period. The freezing time of the mouse 
during the testing period was recorded. During the tone fear retrieval trial on day 2, 
mouse was placed in the same box decorated with colored plastic boards. After a 3 min 
recording for baseline activity, a 20 sec tone similar to day 1 was presented. The freezing 
time of the mouse during the testing period was recorded. All experiments were 
conducted between 9 AM and 5 PM. 
 
 
2.1.9   Cross Maze 
 
Mouse was placed in the entry arm of the cross-maze and allowed to explore 
freely for 5 min with a camera on top. At the end of the study, videos were replayed. The 
pattern of arm choices was recorded and the total number of entries was counted. An 
entry was counted when four limbs of the mouse are in the arm. 
 
 
2.1.10 Morris Water Maze Test 
 
At approximately 2 months of age, the spatial learning and memory in the young 
Nedd4+/- mice and their littermates were evaluated by the Morris water maze test (Morris, 
1984). During the water maze test, mouse was allowed to swim in a circular pool (114 cm 
in diameter). Water was colored with a non-toxic paint to make opaque. A circular escape 
platform of 10 cm in diameter was placed under the surface of the water about 0.5 cm in 
depth, to allow the mouse to escape from swimming. Four trials per day were conducted 
during the visible and hidden platform training. In the visible platform training, the 
submerged escape platform was marked by a visible sign above the surface of the water. 
Mouse was released into the swimming pool at different positions during each of the four 
trials. The latency for the mouse to find the platform was recorded. Mouse that did not 
find the platform in 60 sec was assisted to stay on the platform for an additional 10 sec. 
After the training section, mouse was tested a probe trial, in which the platform was 
removed from the pool and mouse was allowed to swim for 60 sec. The swimming track 
of mouse was recorded. 
 
 
2.1.11 Open Field Test 
 
Mouse was placed in an open-field box (47 × 37 × 20 cm, Accuscan Instruments), 
equipped with 16 infrared beams that automatically measures total locomotor activity by 
beam-breaks and with a camera on top that measures the distance the mouse travelled. 
Mouse was gently placed in the box and allowed to explore freely for 10 min. About 25% 
of the field (47 × 37 × 20 cm) was determined as center. Experiments were performed 
between 9 AM to 5 PM. 
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 2.1.12 Light/Dark Exploration 
 
A plastic chamber (27 × 27 cm in dimension) was used for light/dark exploration. 
The chamber was segregated into opaque and non-opaque compartments. Mouse was 
allowed to transit between the two compartments through a hole on the segregation wall. 
Mouse was placed in the light side and allowed to explore for a 5-min session. The 
movement of mouse was recorded by a camera on top. Several parameters (latency to 
enter the dark, latency to re-enter the light, total time spent in the dark compartment and 
the number of transitions between lighted and dark compartments) were analyzed at the 
end of the study.  
 
 
2.2 Biochemical Studies 
 
 
2.2.1   Cells 
 
The 3T3-L1 preadipocytes were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% bovine calf serum. Cells were split 1:10 every 2 days 
to prevent reaching confluency. For adipocyte differentiation, the preadipocytes were 
allowed to grow to confluency in 10% bovine calf serum. Two days post confluency, 
cells were switched to DMEM supplemented with 10% fetal bovine serum (FBS) and 
stimulated with a differentiation cocktail (IDX) containing 0.5 mM 
isobutylmethylxanthine (IBMX), 1 ?M dexamethasone, and 1.5 ?g/mL insulin. Three 
days after IDX induction, cells were fed with DMEM plus 10% FBS and 1.5 ?g/mL 
insulin. Three days after, cells were cultured in DMEM plus 10% FBS and media was 
replaced every 2-3 days until full differentiation was achieved. The HEK293 cells were 
cultured in DMEM supplemented with 10% FBS. The HEK293 cells stably expressed 
FLAG-tagged ?2-AR (a kind gift from Dr. Suleiman Bahouth at UTHSC) were 
maintained in DMEM plus 10% FBS and 200 ?g/mL of G418. Media was replaced every 
2-3 days. All cells were incubated in 95% O2 and 5% CO2 at 37°C. 
 
 
2.2.2   Adeno-associated Virus (AAV)-mediated Knockdown 
 
AAV-mediated knockdown of NEDD4 was performed by using the 
pAAV2.1.CMV.EGFP-U6.shRNA plasmid vector (a kind gift from Dr. Tonia Rex at 
Vanderbilt University) expressing short hairpin RNA (shRNA) targeting NEDD4 mRNA. 
Of three different shRNA constructs tested, the one showing most effective 
downregultion of NEDD4 protein and Nedd4 mRNA (?50%) was chosen for subsequent 
studies. The targeting sequence is TGG CGA TTT GTG AAC CGT A. Virus production 
was performed by the Gene Transfer Vector Core at the University of Iowa.  
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 2.2.3   Western-blot Analysis 
 
Cells or tissues were lysed with radioimmunoprecipitation (RIPA) buffer 
supplemented with protease and phosphatase inhibitors. Cell debris in lysates was 
removed by centrifugation at maximum speed at 4°C. Protein concentrations were 
determined by the bicinchoninic acid (BCA) method (Pierce). Five to 40 ?g of protein of 
each sample was electrophoresed on a Novex 4–20% Tris-Glycine gel (Invitrogen). After 
transferring the proteins to PVDF membrane, the membrane was blocked at RT in 1 × 
Tris Buffered Saline plus 0.05% Tween-20 (TBST) containing 5% non-fat dry milk for 1 
hr. After blocking, membrane was incubated overnight at 4°C in primary antibody diluted 
in TBST/5% BSA/0.02% NaN3. On the second day, the membrane was washed 
thoroughly with TBST and incubated in secondary horseradish peroxidase (HRP) linked 
antibody (GE Healthcare Life Sciences). Blot was washed three times with TBST 
followed by incubation with enhanced chemiluminescence (ECL) for signal development.  
 
 
2.2.4   Co-immunoprecipitation (Co-IP) 
 
Cells were lysed in a co-IP buffer (25 mM Tris-HCl, 150 mM NaCl, and 1% NP-
40) supplemented with protease and phosphatase inhibitors. After determining protein 
concentrations, 300-1,000 ?g of total protein was resuspended in co-IP buffer. Then, 1-3 
μg of antibody and 30 μl of protein A/G beads (Santa Cruz) were added to each sample 
for overnight incubation with gentle shaking at 4°C. On the second day, beads were 
centrifuged at 8,000 rpm for 2 min, washed three times with the co-IP buffer, and finally 
resuspended in 1 × SDS sample buffer and denatured in boiling water for 5 min. Samples 
were centrifuged again at maximum speed and the resulting supernatant was loaded 
directly on a Tris-Glycine gel or stored at -80°C until use. 
 
 
2.2.5   RNA Isolation, cDNA Synthesis, and qRT-PCR 
 
Total RNA was isolated using Trizol reagent (Invitrogen). For the 3T3-L1 
adipocyte samples, 500 ?l Trizol reagent was applied per well in a 12-well plate; for 
adipose tissue samples, 1 ml Trizol reagent was applied per 50-100 mg of tissue. Cells 
were lysed by scraping or using a homogenizer. A proportional volume of chloroform 
was added to the samples (0.2 ml per 1 ml of Trizol reagent used) and mixed thoroughly 
by shaking for 15 sec. The homogenates were allowed to sit at RT for 2-3 min, and 
subjected to centrifugation at 12,000 × g for 15 min. The following steps were performed 
as described previously (Li et al., 2014). Primers used are listed in Table 2.1.  
 
 
2.2.6   Crude Membrane Fraction 
 
For crude membrane fraction from primary adipocytes, epididymal WAT was 
minced and digested in KRB buffer (pH 7.4) supplemented with 3% fatty acid-free BSA 
fraction V, 0.5 mM adenosine, and 1 mg/mL type I collagenase at 37°C for 45 min. After 
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 Table 2.1 Primers Used for qRT-PCR. 
 
Name Forward Primer Sequences Reverse Primer Sequences 
Leptin caggatcaatgacatttcacaca gctggtgaggacctgttgat 
MIP-?? atgaaggtctccaccactgc cccaggtctctttggagtca 
MCP-1 catccacgtgttggctca gatcatcttgctggtgaatgagt 
F4/80 cctggacgaatcctgtgaa tcccagagtgttgatgcaaa 
???? ccctcacactcagatcatcttct gctacgacgtgggctacag 
???? agcttcaggcaggcagtatc gtcacagaggatgggctctt 
IL4 ggtctcaacccccagctagt? gccgatgatctctctcaagtgat 
IL10 ctggacaacatactgctaaccg gggcatcacttctaccaggtaa 
UCP1 ggcctctacgactcagtcca taagccggctgagatcttgt 
UCP2 tttgggtttggttgtttttga ggaggcagatgcaggtagat 
UCP3 tacccaaccttggctagacg gtccgaggagagagcttgc 
PGC-?? gaaagggccaaacagagaga gtaaatcacacggcgctctt 
PGC-?? ctccagttccggctcctc ccctctgctctcacgtctg 
CIDEA ttcaaggccgtgttaagga cctttggtgctaggcttgg 
PRDM16 cctaaggtgtgcccagca caccttccgcttttctaccc 
NEDD4 acgtgctgttcactgctgat tcacaactcgtgtgtcatcg 
aP2 ggatggaaagtcgaccacaa tggaagtcacgcctttcata 
?????? gagcaaaaatgtgccttgatatt tgcacccttcatttttctcac 
????? gaaagacaacggacaaatcacc gggggtgatatgtttgaacttg 
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 digestion and three washes with KRB plus 3% fatty acid-free BSA, the dissociated 
adipocytes were resuspended in one volume of STE buffer (10 mM Tris-HCl pH 7.5, 1 
mM EDTA pH 8.0, 250 mM sucrose) prewarmed to 37°C supplemented with protease 
and phosphatase inhibitors. The adipocytes were homogenized at RT by six strokes of a 
large-bore Potter-Elvehjem homogenizer (Arthur H. Thomas Co.) fitted with a serrated-
edge Teflon pestle. The homogenizer was driven by an Eberbach Con-torque motor 
operating at maximum speed. The homogenate was then transferred to a round bottom 
tube and spun at 50,000 × g for 30 min at 4°C. The pellet which contains the crude fat 
cell membrane was resuspended in 10 volumes of 50 mM Tris-HCl, 10 mM MgCl2, pH 
8.0 containing protease and phosphatase inhibitors at 4°C and homogenized for 10-
strokes as mentioned above. The homogenate was spun at 15,000 × g for 15 min at 4°C. 
The pellet was resuspended in RIPA buffer on ice for at least 1 hr. The lysate was spun 
again at maximum speed. The supernatant which contains the membrane proteins was 
transferred to a new tube for subsequent analysis.  
 
For crude membrane fraction from HEK293 cells, cells were homogenated in one 
volume of STE buffer plus protein and phosphatase inhibitors by passing through a 25 
gauge needle. The homogenates were transferred to a round bottom tubes and spun at 
50,000 × g for 30 min at 4°C. The pellet was washed once in STE buffer containing 
protease and phosphatase inhibitors and spun again at 50,000 × g for 30 min at 4°C. The 
pellet was dissolved in RIPA buffer on ice for at least 1 hr. The lysate was spun again at 
maximum speed. The supernatant which contains the membrane proteins was transferred 
to a new tube for subsequent analysis. 
 
 
2.2.7   Oil Red O Staining in Differentiated 3T3-L1 Cells 
 
A stock Oil Red O solution was prepared by weighing out 150 mg of Oil Red O 
powder and adding this to 50 mL of isopropanol. Then, 3 parts of Oil Red O stock 
solution with 2 parts distilled water were mixed and incubated for 10 min at RT. The Oil 
Red O working solution was filtered through Whatman filter paper. For Oil red O 
staining of differentiated 3T3-L1 adipocytes, cells cultured in a 35 mm dish were first 
fixed in 10% formalin for 30-60 min. Cells were then briefly rinsed with 3 times with 
distilled water and incubated with 60% isopropanol for 5 min. Freshly prepared Oil red O 
working solution were added to the cells for 5 min. Cultures were rinsed with RT tap 
water until the water rinses were clear. 
 
 
2.2.8   Dual Luciferase Reporter Assay 
 
HEK293 cells of relatively equal numbers were plated on 24-well plates. On the 
second day, seeded cells were transiently cotransfected with 250 ng 3 ??PPRE-Luc, 250 
ng ?????2-Flag, 10 ng Renilla luciferase control reporter vector pRL-SV40 and 250 ng 
of other plasmids using Lipofectamine 2000 transfection reagent (Invitrogen). At 32 hr 
after the transfection, cells were ???????????????????????????????????????????????????????? 
At 48 hr after the transfection, luciferase assay was performed by a dual luciferase assay 
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 system (Promega) according to the manufacturer’s instructions. The luciferase activity 
was adjusted by the Renilla luciferase activity to remove the variation caused by 
transfection efficiency. As NEDD4 overexpression or knockdown did not affect the 
survival of HEK293 cells, we did not normalize the luciferase activity to protein content. 
 
 
2.3 Materials 
 
 
2.3.1   Antibodies  
 
Anti-NEDD4 was purchased from Millipore; anti-?1-AR (V-19), anti-?2-AR (H-
20), anti-CEBP/? (D-5), and anti-PPAR? (E8) mouse monoclonal antibodies were 
purchased from Santa Cruz; another anti-PPAR? rabbit polyclonal antibody was from 
Thermo Scientific; anti-phospho-IGF-1??????????????????IR???????????????????????? 
anti-???, anti-IGF-1R?, anti-AKT, anti-AKT (Thr308), anti-AKT (Ser473), anti-STAT3, 
anti-STAT3 (Tyr705), anti-mTOR, anti-mTOR (Ser2448), anti-AMPK, and anti-AMPK 
(Thr172) antibodies were from Cell Signaling Technology.  
 
 
2.3.2   Reagents  
 
Hematoxylin, eosin, Oil Red O, insulin from bovine pancreas, (-)-isoproterenol 
hydrochloride, rosiglitazone, IBMX, dexamethasone, MG-132, cycloheximide (CHX), 
and chloroquine were purchased from Sigma-Aldrich; recombinant mouse leptin from E. 
Coli was from ProSpec; ICI 118,551 hydrochloride, CGP-20712 dihydrochloride, 
xamoterol hemifumarate, and salmeterol xinafoate were from Toris Bioscience. 
 
 
2.3.3   Plasmids 
 
The pcDNA3-PPAR?2-Flag was obtained from Addgene; pRc-CMV-T7-NEDD4-
1-WT and pRc-CMV-T7-NEDD4-1-CS were kind gifts from Dr. Daniela Rotin at The 
Hospital for Sick Children in Canada; pSUPER-shNEDD4 was generated by our 
laboratory (Kwak et al., 2010); PPRE ? 3-TK-luc plasmid containing three copies of the 
PPAR response element (PPRE) upstream of a luciferase reporter was a generously 
provided by Dr. Edwards Park at UTHSC. 
 
 
2.4 Statistics 
 
Data were analyzed by GraphPad Prism 5.0. Two-tailed Student's t-test was used 
for statistical comparison between two groups; two-way ANOVA followed by bonferroni 
post-test correction was used for statistical comparison between groups when there were 
two factors.   
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 CHAPTER 3.    METABOLIC PHENOTYPE STUDIES 
 
 
3.1 Introduction 
 
 Obesity results from loss of homeostasis between lipid, protein, and carbohydrate 
metabolism. The delicate balance between protein synthesis and protein breakdown is 
crucial to keep our internal homeostasis under tight control. Protein degradation, or 
proteolysis is one of the strategies employed by the cell to remove abnormal proteins and 
prevent their aggregation, or to irreversibly inactivate proteins that are no longer needed 
(Ciechanover, 2005). The amino acids generated by protein degradation may then be 
reused for protein synthesis.  
 
Besides the cell’s autophagy-lysosome proteolysis, the ubiquitin-proteasome 
proteolysis represents a major protein degradation pathway. Defects in ubiquitin-
dependent proteolysis have been associated with a number of human diseases, including 
metabolic disorders (Sakamoto, 2002). Although there are very few studies published so 
far, the importance of ubiquitin-dependent proteolysis in metabolic regulation is 
increasingly emphasized. The ubiquitin-proteasome system (UPS) requires the sequential 
and cooperative actions of E1, E2, and E3 enzymes. While E1 and E2 enzymes process 
ubiquitin, the E3 ligases are the main enzymes responsible for substrate specificity 
(Scheffner et al., 1995). Several members of the E3 ubiquitin ligase family have emerged 
as regulators of metabolism, as evident in the knockout mice for mitsugumin 53 (Song et 
al., 2013), ITCH (Marino et al., 2014), and two members of the Casitas B-lineage 
lymphoma (Cbl) family—Cbl-b and c-Cbl (Abe et al., 2013; Hirasaka et al., 2007; 
Molero et al., 2004; Molero et al., 2006). The involvement of these E3 ligases in HFDIO 
suggests important roles for E3 ligases in metabolic regulation.  
 
Rsp5p, the most well-studied yeast E3 ligase, participates in important cellular 
processes including lipid and membrane synthesis (Hoppe et al., 2000). Its mammalian 
homologues —NEDD4 and ITCH —are two structurally related E3 ligases belonging to 
the nine-member HECT NEDD4 family. NEDD4 and ITCH both recognize proline-rich 
consensus sequence motifs (e.g., PPxY and PPLP), and thereby ubiquitinate several 
overlapping targets in vitro (Bray, 2006), including the aforementioned Cbl proteins 
(Magnifico et al., 2003). Comparison study of immunity using genetically modified mice 
indicates that they regulate distinct pathways in vivo (Yang et al., 2008). Comparing and 
distinguishing NEDD4 and ITCH regulated pathways in vivo are of particular importance 
to validate them as therapeutic targets. Recently, depletion of ITCH in mice was found to 
reverse HFD-induced obesity and its related metabolic disorders (Marino et al., 2014). 
Since NEDD4 knockout mice are embryonic/perinatal lethal, we created a HFDIO model 
in Nedd4-haploinsufficient mice.  
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 3.2 Results 
 
 
3.2.1   Genotype Verification of Nedd4-haploinsufficient Mice   
  
The Nedd4-haploinsufficient (Nedd4+/-) mice we used in this study were originally 
generated by Lexicon Genetic Incorporated. A gene-trapping vector insertion strategy 
was employed to disrupt the third WW domain between exon 17 and exon 18 (Figure 
3.1A). The gene trap targeted Nedd4+/- mice were generated on a 129/SvEvBrd ? 
C57BL6/J mix genetic background. A breeding pair (a male Nedd4+/- and a female wild 
type) together with a female Nedd4+/- were transferred from Dr. Weichun Lin’s 
laboratory (University of Texas Southwestern Medical Center). The Nedd4+/- mice were 
viable, fertile, and devoid of gross phenotypic defects. However, a null mutation of 
Nedd4 (Nedd4-/-) in mice leads to embryonic or perinatal lethality: most of the Nedd4-/- 
mice died between E15.5-E18.5 before birth with few Nedd4-/- mice born and died on P0 
(Liu et al., 2009). Based on my observation, most of the Nedd4+/- mice could live for at 
least 18 months.  
 
We performed polymerase chain reaction (PCR) genotyping for Nedd4+/- mice 
and western blot analysis for Nedd4+/- and Nedd4-/- P0 neonatal mice, confirming the 
presence of gene trap vector in Nedd4+/- mice; reduction and absence of NEDD4 protein 
in Nedd4+/- and Nedd4-/- P0 neonatal mice, respectively (Figure 3.1B and C). To 
characterize the extent of NEDD4 protein reduction in Nedd4+/- mice in different organs, 
two pairs of Nedd4+/- mice and their wild-type littermates were euthanized. As expected, 
NEDD4 protein levels were reduced at least 50% in all organs tested (Figure 3.1D). 
 
 
3.2.2   Nedd4-haploinsufficient Mice Resist HFD-induced Obesity 
 
To elucidate the physiological role of NEDD4 and to examine the phenotype of 
Nedd4+/- mice, we placed a cohort of 6-week old Nedd4+/- and wild-type mice on either a 
ND (17% calories from fat) or a HFD (60% calories from fat), and monitored their body 
weights until age 9 months. When fed a ND, Nedd4+/- mice were lighter than their wild-
type control mice from 6 weeks of age to until at least 9 months old in both genders (3.66 
± 0.05g in male, 1.90 ± 0.03g in female) (Figure 3.2A). Their weight gain from 6 weeks 
to 9 months old were comparable between Nedd4+/- and wild-type mice (Figure 3.2B), 
suggesting that they grow in similar speed. The Nedd4+/- mice had reduced body mass at 
birth, and this difference in body mass was carried over into adulthood.  
 
Surprisingly, in response to a HFD, there was a profound difference in the 
increase of body weight between Nedd4+/- and wild-type mice in both males and females 
(Figure 3.2A). After 30 weeks of HFD feeding, the total body weight gain in Nedd4+/- 
mice decreased around 30% (P<0.001). At the end of the feeding, mice on ND had 
roughly 15 g increase in body mass in both Nedd4+/- and wild-type mice; the wild- type 
mice on HFD had an average of 43.2 ± 1.0 g increase in body weight, while there was  
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Figure 3.1   PCR and Western-blot Confirmation of Genotypes. 
(A) A gene-trapping vector was inserted to the third WW domain of Nedd4 gene, 
disrupting between exon 17 and exon 18. (B) Representative image of PCR genotyping of 
wild-type (WT) and Nedd4+/- (Het) mice. Amplified DNA fragments were visualized on 
an agarose gel stained with ethidium bromide. The 137-bp amplicon represented the 
mutant allele. (C) Analysis of whole-body tissue lysates from P0 neonatal mice by 
Western blot using an antibody against NEDD4. (D) Western blot analysis was 
performed in protein lysates from various organs, from two 2-month-old males. 
  
27 
  
 
 
Figure 3.2   Nedd4-haploinsufficient Mice on HFD Exhibit Less Weight Gain. 
(A) Body weight curves of littermate mice fed a normal diet (ND) or a high-fat diet  
(HFD) in males and females (n=8-11 per group). Mice at 6-week of age were started to 
be fed a HFD for 30 weeks. Body weights were monitored on a weekly basis. (B) 
Average weight gain after 30 weeks of diet feeding (n=8-11 per group). (C) 
Representative photos of wild-type (WT) and Nedd4+/- (Het) male mice fed a ND or a 
HFD at 22 weeks of age. All data are mean ± SEM; ***P<0.001. 
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 30.6 ± 1.0 g weight gain, 12 g less than the wild-type controls, in Nedd4+/- mice on HFD 
(Figure 3.2B). Representative picture of the mice were shown in Figure 3.2C.  
 
Nonetheless, Nedd4+/- mice had unaltered physical activity, thermogenesis-related 
gene expression in BAT, and consumed calories proportional to their body weights. 
Therefore, activity and metabolism cannot explain the difference in HFD-induced weight 
gain between Nedd4+/- and control mice (Figure 3.3). 
 
To determine if the reduced weight gain was due to decreased body length, we 
measured the length of mice from anus to nose when the mice were anesthetized or 
euthanized, which allows their bodies to stay in a relaxing posture. The average ‘anus-to-
nose’ lengths in gender-matched littermate Nedd4+/- and wild-type mice were similar on 
HFD (Figure 3.4A), suggesting that Nedd4+/- mice are leaner rather than smaller. 
Representative anatomical pictures of mice and dissected fat depots were shown in 
Figure 3.4B. Postmortem dissection for epididymal, inguinal subcutaneous white, and 
interscapular brown fat depots revealed significantly reduced accumulation of visceral 
and subcutaneous fat but not interscapular brown fat in HFD-fed Nedd4+/- mice compared 
to controls (Figure 3.4C). Ratios of epididymal and inguinal subcutaneous WAT mass  
vs. body mass were ~36% lower in Nedd4+/- (4.5 ± 0.5% and 2.8 ± 0.4%) relative to 
control mice (7.0 ± 0.1% and 4.4 ± 0.5%) on HFD (P<0.05) (Figure 3.4D and E). In 
addition, the leptin mRNA levels in epididymal WAT were 32.5% lower in Nedd4+/- mice 
(P<0.05) (Figure 3.4F), consistent with leptin as an indicator of body fat (Caro et al., 
1996). We estimated the lean body mass index by the weight of non-fat tissues, such as 
the liver, heart, kidney, brain, and skeletal muscle (i.e., gastrocnemius and quadriceps),vs. 
body weight. Our data show that the ratio of lean body mass vs. body mass were similar 
between genotypes (Figure 3.4H).  
 
On the ND, the ratios of lean body mass vs. body mass were similar between 
Nedd4+/- and wild-type mice (Figure 3.4G). The observed lack of apparent decrease in 
the weight gain in Nedd4+/- mice on ND (Figure 3.2A) was most likely because their 
increase in lean body mass compensated for the decrease in fat mass; fat mass only 
accounts for a small portion of body mass prior to middle age. These observations 
suggest that protection of Nedd4+/- mice from diet-induced obesity, and even age-induced 
obesity potentially, could have resulted primarily from the reduced fat mass.   
 
 
3.2.3   Nedd4-haploinsufficient Mice Are Resistant to Several HFD-induced 
Deleterious Effects without Changes in Serum Lipid Profile 
 
The expansion of WAT in obesity can be a result of adipocyte hypertrophy 
(increase in cell size) and/or hyperplasia (increase in cell number) (de Ferranti and 
Mozaffarian, 2008; Sun et al., 2011). Histological analysis in the paraffin embedded 
epididymal WAT revealed a significant 25% smaller average cell size in Nedd4+/- mice 
on HFD (Figure 3.5A and B). Cell size distribution analysis showed a greater frequency 
of small and midsized adipocytes and a lower frequency of large adipocytes in 
epididymal WAT from the HFD-fed Nedd4+/- mice, while the distribution curves in the  
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Figure 3.3   Nedd4-haploinsufficient Mice Exhibit Normal Physical Activity, Energy 
Intake, and Thermogenesis-related Gene Expression. 
(A) Mice at ages 12-16 weeks were fed a known amount of food ad libitum. After 24 hr, 
the remaining food was weighed. Consumption of food (absolute food intake) was 
calculated by the difference. Food intake was monitored on a daily basis for a continuous 
7-day period. Food intake was converted to energy intake by multiplying by the energy 
density in food. (B) Relative food intake was calculated as the absolute food intake per 
gram of body weight. (C and D) Animals were individually placed for 10 min in a novel 
open-field box equipped with beams that automatically measure total locomotor activity 
by beam breaks. (C) Total number of beam breaks indicates total activity. (D) Total 
distance traveled in inches. ND, n=14-23 per group; HFD, n=8-10 per group. (E) Relative 
mRNA levels of thermogenic genes in BAT in littermates WT and Het on ND or HFD 
were measured by qRT-PCR (ND, n=3 per group; HFD, n=5-6 per group). Data represent 
mean ± SEM; * P<0.05; n.s. no significance.  
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Figure 3.4   Nedd4-haploinsufficient Mice on HFD Have Reduced Fat Mass. 
(A) Average ‘anus-to-nose’ lengths in gender-matched wild-type (WT) and Nedd4+/-(Het) 
littermates. n=5 per group. (B) Representative anatomical views of mice fed a HFD. (C) 
Epididymal (Epi) and inguinal subcutaneous (SubQ) fat pads were dissected from WT 
and Het mice on ND or HFD. (D) Epi, SubQ and BAT depot weights in gender-matched 
littermates WT and Het at 22 weeks of age. (E) Percentage of fat pad weights to the body 
weights. n=5-7 per group. (F) Leptin mRNA levels in Epi by qRT-PCR analysis (ND n=3 
per genotype; HFD n=5-6 per genotype). (G and H) Percentage of organ weights to the 
body weights on ND (G) or on HFD (H) (n=5-7 per group). All data are mean ± SEM; 
*P<0.05, **P<0.01 and ***P<0.001. 
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Figure 3.5   Nedd4-haploinsufficient Mice Are Protected against HFD-induced 
Adipocyte Hypertrophy. 
(A) Representative H&E staining of adipocytes. (B-D) Mean (B) and distribution (C and 
D) of adipocyte size in epididymal adipose tissue of wild-type (WT) and Nedd4+/- (Het) 
littermates on ND (C) or HFD (D) (n=3-4 per group). The area of adipocytes was 
measured for 300-400 cells per mouse using ImageJ software with “Adipocytes Tools” 
plug-in. Scale bar=100 ?m. All data are mean ± SEM; *P<0.05, **P<0.01, *** P<0.001. 
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 ND-fed Nedd4+/- and wild-type mice were almost overlapping (Figure 3.5C and D). 
Hence, NEDD4 downregulation in obese mice was associated with reduced adipocyte 
volume indicating lower degrees of lipid accumulation within adipocytes. 
 
Chronic HFD leads to TG accumulation in liver called non-alcoholic fatty liver or 
hepatic steatosis (Motomura et al., 2006). After 16 weeks of HFD, hepatocytes of wild-
type mice were filled with multiple large lipid droplets, whereas Nedd4+/- littermates 
displayed significantly smaller and fewer lipid droplets as detected by hematoxylin and 
eosin stain or oil red O stain (Figure 3.6A and B). These data indicate protection from 
hepatic steatosis in Nedd4+/- mice. 
 
Low-grade inflammation invariably accompanies significant obesity (Wellen and 
Hotamisligil, 2003). As expected, we saw dramatic HFD induced increases in mRNA 
levels of several pro-inflammatory markers (MIP-???? ??-??????????????????????-????
within the WAT of wild-type mice. TNF-???????????????? ?? ???????????????????????
MIP-??????? ??-1 represent two major chemokines essential for recruiting M1 
macrophages (Mantovani et al., 2004). The observed lower transcriptional expression of 
these markers in HFD-fed Nedd4+/- mice compared to wild-type littermates may indicate 
reduced M1 macrophage infiltration in the HFD-fed Nedd4+/- mice. IL4 and anti-
inflammatory IL10, two TH2 cytokines, can induce M2 macrophage polarization 
(Mantovani et al., 2004). Interestingly, IL4 and IL10 mRNA levels were not significantly 
different in WAT between genotypes, suggesting that the attenuation of lipid-induced 
inflammation may be independent of M2 action (Figure 3.7). This is consistent with the 
?????????????????????????????????????????????????????????2) percentages in HFD-fed 
Nedd4+/- and wild-type mice were similar (Figure 3.5D), since M2 macrophages mainly 
present in lean adipose tissue (Fujisaka et al., 2009). Of note, NEDD4 protein levels per 
se were unaltered by HFD in WAT, skeletal muscle, or hypothalamus (Figure 3.8A-C).  
 
Dietary obesity is usually accompanied with enhanced basal lipolysis, resulting in 
increased serum cholesterol, TG, glycerol, and FFA levels.  However, we found unaltered 
serum lipid profile in ND- or HFD-fed Nedd4+/- mice relative to their respective controls 
(Table 3.1). 
 
 
3.2.4   Nedd4-haploinsufficient Mice Retain Insulin Sensitivity in WAT despite HFD 
 
To examine whole body insulin sensitivity, we performed GTT and ITT on age- 
and gender-matched mice at approximately age 22 weeks. In ND-fed Nedd4+/- vs. 
controls, we observed decreased insulin sensitivity during ITT (Figure 3.9B) and a small 
compensatory increase in the serum insulin levels under both fed (3.65 ± 0.28 ng/mL vs. 
2.77 ± 0.27 ng/mL, P<0.01) and fasted (1.11 ± 0.10 ng/mL vs. 0.73 ± 0.08 ng/mL, 
P<0.01) states (Figure 3.9D and E). Consistently, serum insulin levels in ND-fed 
Nedd4+/- during GTT is slightly higher than that in the wild-type mice (P<0.05) (Figure 
3.9C). Despite these defects, ND-fed Nedd4+/- mice were paradoxically glucose tolerant 
with normal basal blood glucose level (Figure 3.9A). Collectively, the data suggest that  
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Figure 3.6   Nedd4-haploinsufficient Mice Are Protected against HFD-induced 
Hepatic Steatosis. 
(A) Representative H&E staining of liver in littermates wild-type (WT) and Nedd4+/-  
(Het) on ND or HFD (n=3). Sections were stained with hematoxylin for nuclei and 
counterstained with eosin. (B) Representative oil red O staining in liver sections from 
WT and Het mice on ND or HFD (n=3). Fixed cryosections were stained with freshly 
prepared oil red O working solution for 15 min and counterstained for nuclei with 
hematoxylin. Scale bar=100 ?m.  
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Figure 3.7   Nedd4-haploinsufficient Mice Are Protected against Lipid-induced 
Inflammation. 
Relative transcriptional levels of inflammatory markers in epididymal fat in littermates 
wild-type (WT) and Nedd4+/- (Het) on ND or HFD were measured by qRT-PCR. ND n=3 
per genotype; HFD (n=5-6 per genotype). Around 50 mg of adipose tissue was lysed in 1 
ml of Trizol for RNA isolation. Around 1 ?g of total RNA was reverse transcribed into 
cDNAs which were subsequently used for qRT-PCR detection with intron-spanning 
primers. All data are mean ± SEM; *P<0.05, **P<0.01. 
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Figure 3.8   NEDD4 Protein Levels Are Not Altered by HFD Feeding. 
Immunoblot analysis of NEDD4 protein levels in epididymal WAT (A), gastrocnemius 
muscle (B) and hypothalamus (C) tissue lysates from WT mice fed on ND or HFD at age 
36 weeks. The IR? levels in WAT served as a positive control of the effect of HFD. The 
GAPDH levels served as loading controls. 
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 Table 3.1 Metabolic Parameters in Serum or Blood. 
 
 WT, ND  Het, ND   WT, HFD  Het, HFD  
Measurements Mean ± SEM n  Mean ± SEM n Statistics  Mean ± SEM n  Mean ± SEM n Statistics 
Glucose (mM)              
Fed 11.46 ± 0.49 12  11.84 ± 0.36 12 n.s.  12.95 ± 0.43 12  13.24 ± 0.56 12 n.s. 
Fasted 8.02 ± 0.57 12  8.73 ± 0.37 12 n.s.  10.29 ± 0.38 12  9.52 ± 0.79 12 n.s. 
Cholesterol (mM)              
Fed 4.30 ± 0.37 10  4.40 ± 0.31 10 n.s.  6.37 ± 0.45 10  6.73 ± 0.45 10 n.s. 
Fasted 2.87 ± 0.50 10  2.65 ± 0.62 10 n.s.  3.48 ± 1.07 10  2.20 ± 1.41 10 n.s. 
TG (mM)              
Fed 2.26 ± 0.31 10  2.65 ± 0.21 10 n.s.  2.74 ± 0.20 10  2.79 ± 0.35 10 n.s. 
Fasted 1.83 ± 0.18 10  1.81 ± 0.20 10 n.s.  2.33 ± 0.39 10  2.53 ± 0.68 10 n.s. 
Glycerol (mM)              
Fed 3.87 ± 0.32 8  3.86 ± 0.29 7 n.s.  6.01 ± 0.35 9  5.85 ± 0.52 6 n.s. 
Fasted 4.92 ± 0.44 8  5.25 ± 0.31 7 n.s.  5.05 ± 0.63 9  3.76 ± 0.59 6 n.s. 
FFA (mM)              
Fed 0.20 ± 0.02 8  0.20 ± 0.02 7 n.s.  0.28 ± 0.02 9  0.28 ± 0.02 6 n.s. 
Fasted 0.17 ± 0.04 8  0.17 ± 0.03 7 n.s.  0.18 ± 0.07 9  0.18 ± 0.08 6 n.s. 
 
Notes: Blood glucose and lipid levels in serum from fed and fasted mice were measured by a glucose meter or respective assay kits. 
Fed glucose levels are higher in HFD groups compared to respective group on ND (WT, P<0.05; Nedd4+/-, P<0.05). Fasting glucose 
and TG levels are higher in WT, HFD compared to WT, ND (P<0.01). Fed cholesterol, TG, glycerol, and FFA levels are higher in 
HFD groups compared to respective group on ND (WT, P<0.001; Nedd4+/-, P<0.001). Each group contains relatively equal numbers 
of male and female. Mice were tested around 22 weeks of age. WT, wild-type mice; Het, Nedd4+/- mice. All data are means ± SEM; 
n.s. no significance. 
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Figure 3.9   GTT, ITT, and Serum Insulin Levels.  
(A) No significant difference in glucose clearance ability between two genotypes (n=12-
19 per group). (B) Under normal diet (ND), Nedd4+/- (Het) mice were less responsive to 
insulin compared to wild-type (WT) littermate controls based on glucose clearance rate 
(n=12-19 per group). (C) Serum insulin levels during GTT (n=12-19 per group with both 
genders). For GTT, mice were fasted overnight and i.p. injected with 1.5 g/kg of glucose. 
For ITT, mice were fasted for 4 hr and i.p. injected with 0.75 U/kg of insulin. Fed (D) 
and fasted (E) serum insulin levels in WT and Het mice on ND or HFD. All data are 
mean ± SEM; *P<0.05, **P<0.01, ***P<0.01.  
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 ND-fed Nedd4+/- mice possess only mildly decreased insulin sensitivity, which can be 
compensated by increased insulin secretion.  
 
In wild-type mice, HFD induced profound glucose intolerance, insulin resistance 
associated with a five-fold increase in the basal circulating insulin concentration, and 
failure of glucose-stimulated insulin secretion (Figure 3.9A-C). Most surprising, 
chronically HFD-fed Nedd4+/- mice displayed same degree of glucose intolerance (Figure 
3.9A and B) despite lower circulating insulin levels (Figure 3.9C-E), compared to HFD-
fed controls (fed, 9.23 ± 0.69 ng/mL vs. 11.8 ± 0.65 ng/mL, P<0.05; fasted, 5.19 ± 0.72 
ng/mL vs. 8.03 ± 0.99 ng/mL, P<0.05) , suggesting that the HFD-fed Nedd4+/- mice 
required less circulating insulin to maintain euglycemia.  
 
To delineate insulin sensitivity in specifically responsive tissues, we analyzed 
insulin-stimulated signaling in WAT, skeletal muscle, and liver. Western blot analysis of 
in vivo insulin signaling in fat, skeletal muscle, and liver demonstrated reduced 
phosphorylation of IR and protein kinase B/AKT (PKB/AKT) evoked by a single i.p. 
insulin injection in ND-fed Nedd4+/- mice (Figure 3.10A-C). Nedd4+/- mice on HFD 
displayed enhanced tyrosine phosphorylation of IR and their downstream PK B/AKT 
only in WAT (Figure 3.10D), but not in skeletal muscle or liver (Figure 3.10E and F).  
 
 
3.3 Summary 
 
NEDD4 is a HECT-type E3 ligase that has been implicated in the downregulation 
of several activated receptor tyrosine kinases in vitro. Genetic knockout of NEDD4 led to 
reduced IGF-1 signaling, suggesting that the role of NEDD4 in this system is more 
complex. Because NEDD4 knockout mice have major embryonic defects, most of the 
current studies regarding NEDD4 function are restricted to mouse embryonic 
development. We found that Nedd4+/- mice were devoid of gross morbidity or mortality 
and therefore can be used for investigating NEDD4 function in adult and/or aging stage. 
Our preliminary studies confirmed several reported substrates of NEDD4 in neuronal 
culture system, such as PTEN and IGF-1R, both of which have central functions in 
insulin/IGF-1 signaling. To study the NEDD4’s role in metabolic regulation, we 
challenged Nedd4+/- mice with a HFD (60% of calories from fat) for 30 weeks. By 
monitoring their body weights weekly, we found a significant difference in weight gain 
between Nedd4+/- and wild-type mice.  
 
Further characterization revealed that the loss of HFD-provoked weight gain in 
Nedd4+/- mice was due to reduced fat content, especially the mass of visceral and 
subcutaneous fat. Although the absolute weights of other non-fat organs were lower in 
Nedd4+/- mice than in controls, their weights were in proportion to their total body 
weights. Histological analysis of adipose tissue showed smaller adipocyte size in Nedd4+/- 
mice. The associated complications, such as lipid-induced hepatic steatosis and 
inflammation, were also attenuated in HFD-fed Nedd4+/- mice. These data suggest that 
Nedd4+/- mice have better ability to attain fat balance upon energy surplus, and therefore, 
resist to obesity development.  
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 Figure 3.10 In vivo Insulin Signaling in WAT, Skeletal Muscle, and Liver. 
Western blot analysis of phosphorylated and total IR? and AKT protein levels in WAT 
(epididymal) (A and D), skeletal muscle (gastrocnemius) (B and E), and Liver (C and F) 
in wild-type (WT) and Nedd4+/- (Het) mice on ND (A-C) or HFD (D-F) with protein 
quantification (n=5-7 per group).Mice at age around 22 weeks were fasted overnight and 
i.p. injected with 5 U/kg of insulin and waited for 15 min before being euthanized. 
Tissues were quickly dissected and snap-frozen until use. All data are mean ± SEM; 
*P<0.05, **P<0.01. 
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 In response to HFD, partial loss of NEDD4 function was associated with reduced 
circulating insulin levels and selective insulin sensitivity improvement in WAT, but not 
in skeletal muscle or liver, despite unalleviated systemic impairment in glucose 
homeostasis. These data suggest that NEDD4 may partially mediate obesity-associated 
insulin resistance. Paradoxically, NEDD4 was required for maintaining normal insulin 
signaling under basal conditions (fed on ND), as Nedd4+/- mice on ND displayed reduced 
insulin signaling in several insulin-sensitive organs (WAT, skeletal muscle, and liver). 
Taken together, these data imply that NEDD4 may have distinct physiological and 
pathophysiological roles in insulin system. 
 
In addition to glucose tolerance, Nedd4+/- mice exhibited similar serum lipid 
concentrations to those of control mice with or without HFD challenge, suggesting that 
NEDD4 has minor roles in regulating glucose homeostasis and blood lipid turnover.Also, 
HFD did not affect NEDD4 expressional levels in several metabolic tissues 
(hypothalamus, skeletal muscle, WAT). 
 
In summary, Nedd4 haploinsufficiency protects against HFD-induced obesity, 
hyperinsulinemia, adipocyte hypertrophy, hepatic steatosis, and pro-inflammatory 
response. However, partial loss of NEDD4 function does not alleviate obesity-associated 
insulin resistance, glucose intolerance, and hyperlipidemia, decoupling obesity from 
several of its associated pathologies. Although the reason why Nedd4+/- mice manifest 
these decoupling effects is unclear, our studies may provide experimental evidence for 
clinical heterogeneity seen in metabolic syndrome. 
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 CHAPTER 4.    MECHANISTIC STUDIES 
 
 
4.1 Introduction 
 
E3 ligases that possess the ability of selecting specific proteins for ubiquitin 
conjugation are important regulators in protein degradation process. NEDD4 is the 
prototypic member in NEDD4 protein family of E3 ligases which contains a C2 domain, 
3-4 WW domains, and a catalytic HECT domain. During the process of ubiquitination, 
the ubiquitin-conjugated E2 binds to the C-terminal HECT domain, initiating a thiol-ester 
exchange to transfer the ubiquitin from E2 to a catalytic cysteine residue within the C-
terminal lobe of the HECT domain (Ingham et al., 2004). HECT domain, therefore, 
transiently receive ubiquitin before its transfer to the substrate. Repetitive occurrence of 
this thiol-ester exchange produces a polyubiquitin chain which targets the substrate 
protein for lysosomal or proteasomal degradation (Wang et al., 1999a). While the C2 
domain regulates cellular translocation of NEDD4, the multiple WW domains which bind 
predominantly to proline-rich motifs (PPxY, PPLP, PR, and phosphoserine/threonine 
residues that precede a proline residue) are mainly responsible for substrate selection by 
NEDD4 (Ingham et al., 2004).   
 
Two mammalian non-visual arrestins (?-arrestin 1 and 2) and the arrestin domain-
containing proteins (ARRDC2-4) have been reported to function primarily as adaptor 
proteins between E3 ligase NEDD4 and ?2-AR (Han et al., 2013b). No proline-rich 
motifs were found in ?-arrestins; mutation in WW domains of NEDD4 did not affect the 
recruitment of NEDD4 to ?2-AR, suggesting that non-canonical binding exists between 
???????????-arrestins (Shenoy et al., 2008). Unlike ?-arrestins, a PPxY motif was 
found in ARRDCs. The ARRDC3 protein interacts with NEDD4 through two conserved 
PPxY motifs (Nabhan et al., 2010). Interestingly, ARRDC3-deficient mice also displayed 
????????????????????????????????????????????? ???????????-adrenergic signaling (Patwari et 
al., 2011) 
 
In Chapter 3 we have carefully characterized the metabolic phenotypes in 
Nedd4+/- mice. We found that Nedd4+/- mice after HFD feeding elicited reduced adiposity, 
due mainly to the smaller visceral and subcutaneous fat depots. In the current chapter, we 
seek to investigate the underlying mechanisms. We examined whether the lipolytic 
efficiency was altered in HFD-fed Nedd4+/- mice as they manifested reduced lipid storage 
and t????2-AR is an essential mediator of lipolysis process in fat. Here, we also 
investigated potential regulation of ????? by NEDD4. Because it has been widely 
accepted that PPAR? plays fundamental regulatory roles in adipose tissue biology and 
pathology: ?????? ??????? not only adipogenesis but also HFD-induced adipocyte 
hypertrophy (Kubota et al., 1999), two important processes controlling adipose tissue 
volume.  
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 4.2 Results 
 
 
4.2.1   Knockdown of NEDD4 Accelerates Lipolysis 
 
Lipolysis rate in response to i.p. injection of isoproterenol (a non-???????????-AR 
agonists) in vivo was similar between ND-fed Nedd4+/- and wild-type mice. However, the 
lipolysis rate in the HFD-fed Nedd4+/- mice was significantly higher than controls 
(Figure 4.1A). To confirm this in vivo finding, we assayed lipolysis ex vivo in purified 
primary adipocytes. Whereas HFD greatly inhibited the isoproterenol-stimulated glycerol 
release in wild-type adipocytes, Nedd4+/- adipocytes remained highly sensitiv??????-AR 
stimulation. Furthermore, preincubation with insulin (a potent anti-lipolytic hormone) of 
primary adipocytes isolated from HFD-fed Nedd4+/- mice completely blocked 
isoproterenol-stimulated glycerol release. This effect was not observed in controls and 
was consistent with respective levels of insulin signaling in WAT?????????????????????1-
???????????2-AR mediated this effect, we preincubated the adipocytes with ICI-118,551 
??????????????2-AR antagonist) or CGP-20??????????????????1-AR antagonist). ICI-118,551 
completely blocked the isoproterenol-stimulated lipolytic response observed in primary 
adipocytes derived from HFD-fed Nedd4+/- mice. CGP-20712 attained only partial 
??????????????????????????????????????????2-AR primarily mediates the enhancement of 
isoproterenol-induced lipolysis related to NEDD4 loss of function. In addition, treating 
?????????????????????????????????????????1-???????2-AR agonists (xamoterol and 
?????????????????????????????????????2-AR as the predominant mediator (Figure 4.1B). 
 
As mice age, their growth rates decrease and fatty acids are largely stored in the 
adipose tissue in the form of TGs, mimicking hyperlipidemia in clinical obesity. To 
investigate the effect of age on lipolysis, a set of age- and gender-matched Nedd4+/- and 
wild-type mice were placed on ND, then followed to age roughly 18 months. We 
obtained epididymal fat tissue explants or purified primary adipocytes to assess lipolysis 
ex vivo. Isoproterenol stimulated significantly higher lipolysis in fat explant from aged 
Nedd4+/- mice, as early as 30 min after incubation (Figure 4.1D). Isoproterenol and 
salmeterol, but not xemoterol, stimulated higher lipolysis rates in adipocytes from aged 
Nedd4+/- mice, confirming accelerated lipolysis in aged Nedd4+/- mice and a primary role 
?????2-AR in this regulation (Figure 4.1C).  
 
 
4.2.2   ??????????????????????????????2-AR Abundance at the Plasma Membrane 
 
????????????????????????????????????????????????????????????????????2-AR, via 
endocytosis and the subsequent lysosomal degradation of active receptors. Recent work 
based on in vitro overexpression suggests NEDD4 is an E3 ligase involved in ?2-AR 
protein degradation (Nabhan et al., 2010; Shenoy et al., 2008). To validate the 
??????????????????????????????????2-AR regulation in vivo —in the context of 
lipolysis,—?????????????????????????????????????????????????????2-AR abundance. 
Whole cell lysates and crude membrane fractions prepared from WAT from HFD-fed 
Nedd4+/- and wild-type mice were analyzed by immunoblot. Despite only a 1.4-fold 
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Figure 4.1   Downregulation of NEDD4 Enhances Hormone-stimulated Lipolysis In 
vivo and Ex vivo.  
(A) Serum free glycerol levels in a cohort of 22-week-old, gender-matched wild-type 
(WT) and Nedd4+/- (Het) mice at indicated time after i.p. isoproterenol, 10 mg/kg (n=5). 
(B) Primary adipocytes purified from epididymal fat of WT and Het mice were 
resuspended in media and incubated with indicated reagents with gentle shaking for 1 hr. 
Insulin, ?-???????????????-antagonists were pre-incubated for 10 min. Glycerol levels in 
conditioned media were measured (n=4). (C) Primary adipocytes were purified from 
epididymal fat of aged WT and Het mice and resuspended in media with indicated 
reagents. Glycerol levels in media were measured after 1-hr incubation (n=5-6).  (D) 
Adipose tissue explants from aged WT and Het mice were resuspended in DMEM 
supplemented with 0.5% fatty acid free BSA and shaken at 400 rpm at 37°C with or 
??????????????????????????????????r. Glycerol levels were normalized to the weights of 
adipose tissue explant (n=4). Data represent mean ± SEM; *P<0.05, **P<0.01, and 
***P<0.001. 
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 ???????????????????2-AR protein levels (Figure 4.2A), a dramatic 2.4-fold increase in 
??????????2-AR levels was detected (Figure 4.2B). These observations suggest that the 
enhanced lipolysis associated with NEDD4 reduction is likely due to increased 
??????????????2-??????????????????????????? ????????? ????????????????????1-AR in 
these experiments, owing to high background with the chosen antibody. Concurrently, we 
observed a 1.5-fold higher level of IR, but not IGF-1R, on the plasma membrane in 
Nedd4+/- mice on HFD (Figure 4.2B), consistent with the observations of elevated insulin 
signaling in WAT. 
 
To confirm these observations in vitro, we employed HEK293 cells with stable 
?????????????????????????????????2-AR at a medium level. Downregulation of membrane 
?2-AR by prolonged isoproterenol incubation was largely rescued by either NEDD4 
knockdown or transient overexpression of a dominant negative NEDD4 (a CS mutant 
lacking E3 ligase activity) (Figure 4.2C).  
 
 
4.2.3   Knockdown of NEDD4 Increases Lipolytic but Inhibits Adipogenic Response 
in 3T3-L1 Adipocytes 
 
NEDD4 is present at high concentration in 3T3-L1 cells. The 3T3-L1 cell line is 
one of the most hard-to-transfect cell lines. Therefore, it is technically difficult to 
completely deplete NEDD4 from 3T3-L1 cells. Using adeno-associated virus (AAV)-
delivery of specific shRNA targeting Nedd4 mRNA (EGFP-tagged), we were able to 
downregulate both Nedd4 mRNA and NEDD4 protein levels by ~50% (Figure 4.3C). 
Knocking down NEDD4 in 3T3-L1 adipocytes produced a subtle but significant increase 
in isoproterenol-stimulated lipolysis. These data suggest that the enhanced lipolytic 
responses observed in HFD-fed or aged Nedd4+/- mice are most likely a direct result of 
NEDD4 downregulation and not a secondary (endocrine) effect from other organs. Since 
3T3-?????????????????????????????????????2-???????????????????????????????????2-AR is 
regulated by NEDD4 in adipocytes (Figure 4.3A). 
 
Another intriguing finding was that knocking down NEDD4 in 3T3-L1 cells by 
AAV-delivered shRNA greatly impeded the efficiency of the preadipocyte-to-adipocyte 
conversion (Figure 4.3B???????? is arguably the central regulator of adipogenesis. To 
??????????????????????????????????? levels, we ?????????????????????????????
shNEDD4 AAV-infected 3T3-L1 adipocytes. Strikingly, we found a similar degree 
(~50%) of PPAR? downregulation to NEDD4 reduction (P<0.001) (Figure 4.3C), 
together with a consistent ~12% reduction in the mRNA levels for aP2 and Cebpa, two 
?????????????????????????????. ???????????????????????????????????????The Pparg 
mRNA levels were not altered in comparison to those infected with scrambled shRNA 
AAV (Figure 4.3D). At terminal differentiation, there were still approximately 50% of 
the cells expressing EGFP-tagged shRNA viruses (Figure 4.3E). 
 
????????????????????????????????????????????? in vivo????? ??????????????
expression in epididymal WAT. Western blot analysis revealed a trend of reduction in the 
???????????????????????????????????????????????????????in both HFD-fed and aged 
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Figure 4.2   Loss of NEDD4 Function I???????????-AR Protein Concentration at 
Plasma Membrane. 
(A) Representative Western ??????????2-AR expression in epididymal WAT of wild-type 
(WT) and Nedd4+/- (Het) mice after HFD (n=4). (B) Representative Western blot for 
crude membrane fraction from primary adipocytes purified from WT and Het mice after 
HFD (n=3). ?????2-AR-Flag overexpressing cells were transfected with control shRNA 
(shControl), NEDD4 shRNA (shNEDD4), NEDD4 WT, or NEDD4 CS mutant. After 24-
?????????????????????????????????????????????? ????????????????????????????????????
Western blot. Data represent three independent experiments. Data represent means ± 
SEM; * P<0.05, ** P<0.01.  
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Figure 4.3   Partial Loss of NEDD4 Function Increases Lipolytic but Inhibits 
Adipogenic Response. 
(A) 3T3-L1 adipocytes were infected with AAV virus for expressing shRNA sequences 
targeting NEDD4 (shNEDD4) or non-targeting shRNA control (shControl), then 
incubated with indicated reagents for 1 hr. Conditioned media were collected and 
centrifuged to remove cell debris. Glycerol concentrations in the media were measured. 
Data represent three independent experiments. (B) 3T3-L1 cells were infected with 
shControl-AAV or shNEDD4-AAV and induced to differentiation as described in 
Chapter 2. Differentiated adipocytes were stained with oil red O and photographed. (C 
and D) Representative Western blot (C) and qRT-PCR (D) analysis in 3T3-L1 adipocytes 
infected with indicated virus. Data represent four independent experiments. (E) 
Differentiated adipocytes were stained with oil red O and photographed. At terminal 
differentiation, there were still approximately 50% of the cells expressing EGFP. Data 
represent mean ± SEM; *P<0.05, **P<0.01 and ***P<0.001.  
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 Nedd4+/- mice (Figure 4.4A and B). The qRT-PCR analysis did not detect significant 
changes in the mRNA levels of these adipogenic transcription factors (Figure 4.4C). 
 
To our surprise, ??????????????????????? ???????????????????????????????????
??????????????????????????????????????????????????tion by rosiglitazone was not altered 
by NEDD4 knockdown, NEDD4 overexpression, or overexpression of a mutant NEDD4 
(C854S) lacking E3 ligase activity (Figure 4.5). These data indicate that NEDD4 altered 
??????abundance at the protein level. 
 
 
4.2.4   Knockdown of NEDD4 Destabilizes ????? Protein 
 
Next, we tested the role of NEDD4 as a regulator of PPAR? protein. Since 
NEDD4 and PPAR? expression are positively correlated, we hypothesized that NEDD4 
acts as a stabilizer for PPAR? protein. To test this hypothesis, we manipulated NEDD4 
expression in HEK293 cells transiently overexpressing PPAR?, and blocked the de novo 
protein synthesis within the cells using cycloheximide. After 6 hr incubation, cells that 
had reduced NEDD4 expression also had significantly lower PPAR? concentration 
(Figure 4.6A and C). NEDD4 or NEDD4-CS upregulation in cells protected PPAR? 
protein from degradation, with most dramatic effect within 4 hr (Figure 4.6B and D), 
suggesting that the stabilization does not require the enzymatic function of NEDD4. 
 
?????????????????? ??????????????????????????????? ????????????????? that 
could serve as a binding site for NEDD4 (Figure 4.7A???????????????????????????
could be pulled down together in overexpressed culture system demonstrating that these 
proteins interact. The same interaction was found in 3T3-L1 adipocytes and mouse WAT 
(Figure 4.7B-D). To in????????????????????????????????????????????????????????? is 
altered during adipogenesis, we co-immunoprecipitated these proteins from 3T3-L1 cell 
lysates collected throughout differentiation. Remarkably, NEDD4-????? interaction was 
the strongest in preadipocytes, then gradually weakened as differentiation continued 
(Figure 4.8). The reciprocal changes observed in the NEDD4-PPAR? interaction and the 
????? levels during adipogenesis strongly suggest a central role for NEDD4 in 
adipogenesis which warrants further investigation.  
 
 
4.3 Summary 
 
In this chapter, we studied potential molecular and cellular mechanisms that lead 
to the "lean" phenotype in Nedd4+/- mice. As shown in the previous chapter, these mice 
had normal energy intake and exhibited similar physical activity to wild-type mice. The 
transcriptional expression of several key thermogenesis-related genes in BAT in Nedd4+/- 
mice was also undistinguishable from that in wild-type animals, suggesting unaltered 
thermogenesis.  
 
Due to resource limitation, we did not examine the basal metabolic rates in these 
mice, therefore, cannot rule out the contribution from basal metabolism. Nonetheless, we  
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Figure 4.4   ???????????????????????????????????????????????????????WAT. 
(A and B)??????????????????????????????????????????????????????????????????-matched, 
HFD-fed, wild-type (WT) and Nedd4+/- (Het) littermates at age 22 weeks (A) and age 18 
months (B) (A, n=7-8; B, n=6). (C) Relative transcriptional levels of aP2, C/EBP? and 
????? in epididymal fat in littermate WT and Het mice on ND or HFD were measured 
by qRT-PCR (ND, n=3, HFD, n=5-6). Data represent mean ± SEM; *P<0.05.  
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Figure 4.5   NEDD4 Has No Direct E???????????????Activity.  
HEK293 cells were seeded in a 24-well plate and left overnight for attachment. Each well 
was transiently co-transfected with 250 ng 3 ??PPRE-Luc, 250 ng ?????2-Flag, 10 ng 
Renilla luciferase control reporter vector pRL-SV40 and 250 ng plasmids indicated under 
each column. After 32 hr of transfection, cells were treated with or without rosiglitazone 
(10 ?M) for 16 hr prior to luciferase assay. Luciferase activity was normalized to Renilla 
activity as a control for transfection efficiency. Data represent three independent 
experiments. 
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Figure 4.6   NEDD4 S????????????????Protein Expression In vitro. 
HEK293 cells were seeded in a 6-well plate and left overnight for attachment. Each well 
was transiently co-transfected with 1 ?g PPAR?-Flag and 1 ?g indicated plasmids. After 
48 hr, cells were incubated with 20 ?M of cycloheximide (CHX) for 2, 4, and 6 hr. (A 
and B) Representative Western-blot image of PPAR? protein levels during CHX-chase 
experiment. (A) NEDD4 knockdown by shRNA. (B) NEDD4 or NEDD4 CS mutant 
overexpression. (C) Quantification data for the effect of NEDD4 knockdown on PPAR? 
protein levels. (D) Quantification data for the effect of NEDD4 or NEDD4 CS mutant 
overexpression on PPAR? protein levels. Data represent three independent experiments. 
Data represent mean ± SEM; *P<0.05, **P<0.01; n.s., no significance. 
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Figure 4.7   NEDD4 Interact with ?????. 
(A) Sequence alignment of PPxY motif ???????????? in various species. (B) Co-
immunoprecipitat???????????????????-L1 adipocytes with 1 ?g of anti-????? antibody 
(E8, Santa Cruz) and 500 ?g of extract. Co-IP using normal mouse IgG served as 
negative control. (B) Co-immunoprecipitat??????????????????????????????????????
transiently overexpressing plasmids containing NEDD4 and ?????2 with respective 
antibodies. Lysates pulled down with anti-IgG served as negative control. (D) Co-
immunoprecipitation of NE????????????????500 ?g protein lysates of epididymal WAT 
dissected from wild-type (WT) and Nedd4+/- (Het) mice. 
 
  
53 
  
 
 
Figure 4.8   NEDD4-????????????????????????????????????????????????????????????
3T3-L1 Cells. 
(A) Oil red O staining on 3T3-L1 cells incubated with or without IDX cocktail (0.5 mM 
IBMX, 1 ?M dexamethasone, and 1.5 ?g/mL insulin). Picture was taken at 7 days after 
IDX treatment. (B) After indicated time of differentiation, 3T3-L1 cells were harvested, 
immunoprecipitated with an antibody against PPAR? (Santa Cruz E8), followed by 
NEDD4 Western blot. Whole cell lysates (input) were immunoblotted for indicated 
proteins. Co-IP antibody: 1 ?g; extract: 500 ?g; input: 20 ?g. Data represent two 
independent experiments. 
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 provide substantial evidence from in vivo and in vitro experiments implying that NEDD4 
is a regulator of two important pathways in lipid metabolism, i.e. lipolysis and 
adipogenesis, via modulating ?2-AR and PPAR? functions. Isoproterenol stimulated more 
glycerol release in Nedd4+/- mice and isolated Nedd4+/- adipocytes, suggesting enhanced 
?-adrenergic signaling. Data from the treatments of different ? agonists or co-incubation 
of isoproterenol with specific ? antagonists suggested that ?2-AR primarily mediated the 
enhanced lipolytic response by NEDD4 downregulation. Concurrently, Western blot 
analysis of total and membranous ?2-ARs in adipose tissue revealed higher expression of 
the receptor, especially membranous receptor in Nedd4+/- mice. NEDD4 knockdown or 
overexpressing a dominant negative NEDD4 increased ?2-AR levels in crude membrane 
fractions from HEK293 cells stably expressing Flag-?2-AR. These data support a 
previously identified NEDD4's role as an E3 ligase for ?2-AR protein degradation 
(Shenoy et al., 2008). 
 
Using 3T3-L1 cells as a model, we found that downregulation of NEDD4 in 3T3-
L1 preadipocytes inhibited their adipogenic response by the IDX cocktail. The protein 
but not mRNA level of PPAR?, a key adipogenic transcription factor, was also reduced in 
NEDD4 knockdown 3T3-L1 cells. We confirmed this positive correlation between 
NEDD4 and PPAR? in vivo in WAT from both HFD-fed and aged mice. Overexpression 
of NEDD4 stabilized ectopically expressed PPAR?, while NEDD4 knockdown 
destabilized it. This stabilization effect appeared to be independent of NEDD4's ubiquitin 
ligase function, as overexpression of a dominant negative form of NEDD4 could stabilize 
PPAR? to similar extend as wild type NEDD4. Moreover, NEDD4 and PPAR? could be 
co-immunoprecipitated as a complex; their interaction was strongest in preadipocytes and 
gradually attenuated during adipocyte conversion further indicating an important role of 
NEDD4 in adipogenesis. 
 
In summary, the delayed development of HFDIO in Nedd4+/- mice can be 
explained at least through the NEDD4-mediated regulation of lipolysis and adipogenesis 
pathways. These findings again support a novel role of NEDD4 in the molecular 
pathophysiology of obesity. 
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 CHAPTER 5.    NEUROBEHAVIORAL ANALYSES 
 
 
5.1 Introduction 
 
Ubiquitin-mediated proteolysis, being undeniably important for most intracellular 
processes, is increasingly recognized as a critical mechanism in the regulation of 
neuronal development and function in the brain. In Chapters 3 and 4, we have studied 
NEDD4’s role in metabolic function in the context of obesity. In the current chapter, we 
will extend our investigation to NEDD4’s neuronal functionality.  
 
A unique morphological feature of neurons is that they possess axons and 
dendrites (collectively known as neurites), which are projections of neurons that serve to 
transmit electrical/electrochemical signals. Neurons are connected to each other with 
their neurites to form neural networks. Typically, a neuron propagates electrical signals 
through its axon. At the axon terminal, electrical signals trigger release of 
neurotransmitters which can be received by dendrites from other neurons. The axon 
terminal, the receiving surface of dendrite, and the cleft in between constitute a synapse, 
whose plasticity (i.e. synaptic plasticity) plays important role in learning and memory.  
 
NEDD4 is highly expressed in mammalian neurons. Through modulation on its 
neuronal substrates, it has been implicated in at least four aspects of neuronal physiology 
—that is neurite outgrowth, neuron survival, ion channel functions, and neurotransmitter 
signaling. Two studies in 2010 demonstrated an integral role of NEDD4 in the growth 
and branching of neurites: Drinjakovic et al. reported that disrupting NEDD4 function 
severely inhibits the terminal branching of retinal ganglion cell axons by downregulating 
PTEN (Kawabe et al., 2010). Similarly, using both conventional and conditional NEDD4 
knockout mice, Kawabe et al. identified NEDD4 as an important player in promoting 
dendrite formation through inhibiting Rap2A function (Kawabe et al., 2010). In addition, 
NEDD4 was involved in regulating neuronal survival via targeting PTEN for degradation 
in neurons, as demonstrated previously in our laboratory (Kwak et al., 2010). Also, 
NEDD4 was able to decrease whole cell Ca(v) currents by downregulating Ca(v) calcium 
channels (Rougier et al., 2011) and to mediate agonist-dependent ubiquitination and 
degradation of GluA1-containing?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPAR) (Schwarz et al., 2010). Most of these studies were conducted either in 
vitro or at the embryonic stage, raising an interesting question about the NEDD4’s 
neuronal physiological roles in postnatal life.  
 
The sporadic Alzheimer's disease (AD), the most common form of dementia, has 
been increasingly linked to T2D. Some even term AD as "type 3" diabetes, as many 
observations in AD brains reflect similarities in T2D, such as insulin resistance and 
reduced glucose utilization in the brain (Liao and Xu, 2009; Steen et al., 2005). In 
addition, several lines of evidence indicate that boosting insulin signaling in the brain via 
intranasal insulin administration improves cognition in AD patients(Benedict et al., 2004; 
Craft et al., 2012; Dhamoon et al., 2009; Reger et al., 2008). One of the research interests 
in our laboratories is to identify the molecular links between these two types of disease. 
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 Previous studies from our laboratory and others(Cao et al., 2008; Drinjakovic et al., 2010; 
Kawabe et al., 2010; Kwak et al., 2012) demonstrated that NEDD4 is involved in 
insulin/IGF-1 signaling, neurite development, and is likely implicated in AD progression, 
as the expression levels of NEDD4 are increased in postmortem AD brains. Here, we 
investigated whether heterozygous deletion of Nedd4 in mice can alter CNS metabolism 
(insulin signaling, in particular) which may lead to neurobehavioral alteration in vivo. 
 
 
5.2 Results 
 
 
5.2.1   Nedd4-haploinsufficient Mice Have Improved Fear-associated Memory 
 
Fear conditioning is an experimental paradigm to study fear associated memory. 
Normally, animals are challenged with electric shocks paired with a certain context (e.g. 
a room) and a certain cue (e.g. a tone). After a period of time, the fear response of 
animals (freezing) is tested when re-exposed to the same context or cue. This is a form of 
learning and memory mainly dependent upon a brain region called amygdala. But the 
contextual fear conditioning is believed to involve also hippocampus (Phillips and 
LeDoux, 1992). When exposing to foot shock, Nedd4+/- and control mice displayed 
similar immediate freezing response, indicating that there is no difference in their 
threshold for pain (Figure 5.1A). After 24 hr, we placed these mice individually in boxes 
with changed context (decoration and bedding), played the same cue again as on day 1, 
and recorded their freezing time. The result showed no significant difference in cued fear 
conditioning (Figure 5.1B). Another 3 hr after tone test, we placed these mice back in 
exactly the same box as on the training day. The Nedd4+/- mice showed higher freezing 
response than their wild-type littermates (1.4-fold, P<0.01), suggesting better fear-
associated memory in the Nedd4+/- mice (Figure 5.1C). 
 
 
5.2.2   Nedd4-haploinsufficient Mice Display More Spontaneous Alternation 
 
The cross maze is a behavioral test commonly used for assessing animals’ spatial 
learning and memory, which is believed to depend on the function of hippocampus 
(Lalonde, 2002). Rodents possess a strong tendency on arm alternation, which is they 
prefer to explore new arms. The “smart” mice should remember which maze arm was last 
visited. Therefore, recording the orders of their entries is used as an index of the spatial 
reference memory. We placed a cohort of Nedd4+/- and wild-type mice individually in a 
standard cross maze and recorded their order of arm entries. At the end of the test, the 
total number of arm entries and alternation were analyzed. Interestingly, the Nedd4+/- 
group had significantly higher percentage of alternation (36.0 ± 2.8% vs. 27.4 ± 1.8%, 
P<0.01) than wild-type group (Figure 5.2), indicating better spatial working memory in 
Nedd4+/- mice. 
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Figure 5.1   Improved Fear-associated Memory in Nedd4-haploinsufficient Mice. 
(A) Immediate freezing score during the first day training (n=23-46 per group). Time 
intervals for the fear conditioning training on day 1. m1: minute 1, 0–60 s; m2: minute 2, 
60–120 sec; m3: minute 3, 120–180 sec; tone 1: 180–200 sec; iti: inter-tone interval, 
200–260 sec; tone 2: 260–280 sec; end: 280–340 sec. (B and C) Freezing score during 
retrieval tone test (B) or contextual test (C) on day 2 (n=23-46 per group). Time intervals 
for the tone retrieval test on day 2: pre-tone: 0–180 sec; tone: 180–200 sec. Time interval 
for the context fear retrieval test on day 2: context: 60–180 sec. Data represent mean ± 
SEM; **P<0.01; n.s., no significance.  
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Figure 5.2   Improved Learning and Memory in Cross Maze Test in Nedd4-
haploinsufficient Mice. 
(A) Total number of arm entries in Nedd4+/- (Het) and wild-type (WT) mice (n=14-23 per 
group). (B) Ratios of spontaneous alternation versus total entry number (n=14-23 per 
group). Data represent mean ± SEM; *P<0.05, **P<0.01.  
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 5.2.3   Nedd4-haploinsufficient Mice Display Impaired Water Maze Performance 
 
Fear conditioning and cross maze indicate different forms of memory (associative 
and working), but both tests can sometimes be compromised by anxiety/depression. In 
order to confirm phenotype of improved learning and memory in Nedd4+/- mice, we 
performed a third behavioral test, the Morris water maze test, which has become the 
"gold standard" for assessing hippocampus-dependent spatial learning and memory. To 
our surprise, the Nedd4+/- mice displayed severely impaired learning and memory in  
water maze task. While the latency in wild-type group started from ~36 s and dropped to 
~12 s at the end of the training, the average latency in Nedd4+/- mice remained above 30 
sec at day 10 (Figure 5.3A). In the probe test where the hidden platform was removed 
and mice were allowed to swim in the pool freely for 60 s, unlike the wild-type mice that 
spent most of the time swimming around the site of hidden platform, Nedd4+/- mice swam 
across four platforms randomly (Figure 5.3B).These mice took much longer time in 
finding the hidden platform, suggesting that they had impaired spatial learning and 
memory abilities. Brain insulin signaling has been implicated in spatial memory 
processing (Zhao et al., 1999). To examine the brain insulin signaling in Nedd4+/- mice, 
we dissected cortical tissue from P0 mouse brain and stimulated the tissue with insulin. 
Interestingly, we found that the insulin signaling in cortical tissue appeared to be 
attenuated in Nedd4+/- mice in a dose- and time-dependent manner, especially within 15 
min of insulin administration (Figure 5.4). 
 
 
5.2.4   Nedd4-haploinsufficient Mice Display Anxiety-like Behavior 
 
When testing the physical activity of Nedd4+/- mice in an open field test, we found 
that although the total activity and distance traveled were not distinguishable between 
Nedd4+/- and wild-type mice, Nedd4+/- mice spent significantly less time in the center of 
the field (Figure 5.5), This indicates anxiety-like behavior as mice prefer to stay or travel 
close to the side of the box. To confirm this observation, we tested these mice in a 
light/dark box test, which is widely used in the assessment of anxiety. Interestingly, 
Nedd4+/- mice made fewer transitions and tended to stay in the dark compartment, 
suggesting higher anxiety levels in Nedd4+/- mice than controls (Figure 5.6). 
 
 
5.3 Summary 
 
In the current chapter, we studied the in vivo neuronal behavioral outcome using 
Nedd4+/- mice. We found that the partial loss of NEDD4 function is sufficient to cause 
several neurobehavioral alterations using different experimental paradigms, including 
fear conditioning, cross maze, Morris water maze, open field and light/dark box test. The 
seemingly paradoxical observations are that Nedd4+/- mice performed in opposing trends 
in different behavioral paradigms. However, these behavioral tests index distinct working 
memory. For example, the contextual fear conditioning is a form of fear-associated 
memory which involved functions of amygdala and hippocampus. Although cross maze 
and Morris water maze are both tests for assessing rodents’ working memory, they are  
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Figure 5.3   Impaired Learning and Memory in Morris Water Maze Test in Nedd4-
haploinsufficient Mice.  
Mice were 2 months old at the beginning of the test. The apparatus is a circular pool 
filled with RT water made opaque with non-toxic paint. An escape platform was 
submerged 0.5 cm below the surface of the water (up-right), to allow the mice to escape 
from swimming. (A) Latency to find the target platform in the Morris water maze. Both 
groups had identical swim speed as indicated in the visible section. Nedd4+/- (Het) mice 
spent more time in finding the hidden platform compared to their littermate wild-type 
(WT) mice from day 3 to day 10 (n=14-23 per group). (B) Representative pictures of 
swim path in maze during probe trial. Data represent mean ± SEM; **P<0.01.  
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Figure 5.4   Partial Loss of NEDD4 Reduces Insulin-stimulated IR 
Autophosphorylation.  
Dose-response and time-course studies of IR? phosphorylation levels in cortex in 
littermate wild-type (WT) and Nedd4+/- (Het) P0 neonatal mice. (A) The cortical tissue 
was incubated with different doses of insulin for 15 min. (B) The cortical tissue was 
incubated with 1 μM insulin for indicated times. The bottom panels are protein 
quantification results. Data represent three independent experiments. All data are mean ± 
SEM; *P<0.05. 
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Figure 5.5   Locomotor Activity Test Indicates Anxiety-like Behavior in Nedd4-
haploinsufficient Mice.  
Mouse was placed in an open-field box, equipped with infrared beams that automatically 
measures total locomotor activity by beam-breaks and with a camera on top that 
measures the distance the mouse travelled. Mouse was allowed to explore freely in a 10-
min session. (A) Total number of beam breaks indicates total activity. (B) Total distance 
traveled in inches. (C) Nedd4+/- (Het) mice spent less time in center than the wild-type 
(WT) mice, indicating increased anxiety levels (ND n=14-23 per group, HFD n=8-10 per 
group). Data represent mean ± SEM; *P<0.05.   
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Figure 5.6   Light/dark Box Test Indicates Anxiety-like Behavior in Nedd4-
haploinsufficient Mice.  
Anxiety responses are assessed in a chamber segregated into opaque (dark) and non-
opaque (light) compartments. Camera recorded the movement of the mice between 
compartments. (A) Nedd4+/- (Het) mice had less number of transitions between light and 
dark compartments than the wild-type (WT) mice. (B) Het mice traveled shorter distance 
in the light compartment than the WT mice. (C) Moving speeds were identical between 
two groups. (D) Het mice spent less time in the light compartment. (E) Percentage of 
time spent in light compartment was less in Het group. These data indicate that Het mice 
have increased anxiety levels, as mice have a preference for darkness (n=14-23 per 
group). Data represent mean ± SEM; *P<0.05, **P<0.01. 
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 different in that the prior one is for assessing the short-term memory, while the latter one 
is for the long-term memory. In Chapter 3, we have shown that NEDD4 regulates insulin 
signaling in peripheral insulin sensitive tissues under basal condition (ND feeding). Here, 
we show that the insulin signaling in cerebral cortex in neonatal mice was also 
diminished. The impaired long-term spatial working memory of Nedd4+/- mice might be a 
result of their attenuated insulin signaling in the brain, as central insulin actions are 
known to have modulatory roles in long-term memory consolidation (Dou et al., 2005). 
This hypothesis awaits validation in future investigation.  
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CHAPTER 6.    DISCUSSION 
 
 
NEDD4 is the prototypical protein in a family of E3 ligase which has a conserved 
role in mediating ubiquitin-dependent endocytosis and/or degradation of plasma 
membrane proteins. In Chapters 3 and 4, we reported that Nedd4+/- mice, despite being 
moderately insulin resistant, were protected against diet-induced obesity and hepatic 
steatosis. This provides the first evidence for the involvement of NEDD4 in metabolic 
regulation. Further, we showed that NEDD4 regulates ?-adrenergic-mediated lipolytic 
response in vivo and ex vivo. This is consistent to a previous in vitro study of NEDD4-?2-
adrenergic receptor regulation by Shenoy et al. (Shenoy et al., 2008). In addition, 
Nedd4+/- mice under obesogenic (HFD or aged) conditions were accompanied with 
?????????????????????????????????????? adipose tissue. NEDD4 interacted robustly with 
??????in vitro and in vivo by co-immunoprecipitation. Downregulation of NEDD4 by 
shRNA-targeting strategy in 3T3-L1 preadipocytes impaired the adipogenic response, 
???????????????????????????????????????????? Thus, our study has identified, for the first 
time, a positive regulation between NEDD4 and PPAR? in adipocytes. These findings are 
significant since adipose tissue mass is directly related to the risk of progression from 
insulin resistance to T2D (Magre et al., 2001). In Chapter 5, we provided preliminary 
data on several neurobehavioral phenotypes of Nedd4+/- mice, including altered learning 
and memory abilities and anxiety levels; we also found reduced insulin signaling in 
cortical neurons in neonatal Nedd4+/- mice, indicating an integral role of NEDD4 in 
maintaining normal neuronal insulin sensitivity and brain function. In summary, our 
studies provide solid evidence for the involvement of NEDD4 in the regulation of both 
peripheral metabolism and CNS functions. In this chapter, we attempt to place our studies 
in context of other published work. We will also discuss the pitfalls of our experiments 
and implication of the data for future studies. 
 
 
6.1 Pathophysiological Roles of NEDD4 in Obesity 
 
There are a variety of animal models used for obesity research. The most 
commonly used are the following four categories: genetically derived (ob/ob mice, db/db 
mice and Zucker rats), diet-induced (rodents fed a HFD containing 32-60% of calories 
from fat), surgically (ventromedial hypothalamic-lesioned rodents) and chemically (gold 
thioglucose-treated mice) induced obesity (Lutz and Woods, 2012). Here, we chose to 
use a specific HFD containing 60% of calories from fat (mostly lard), which induces 
rapid weight gain and fat accumulation in several strains of mice. One of these quick 
responders is the C57BL/6J strain of mice. A HFD with 60% of fat can trigger weight 
gain and glucose intolerance in C57BL/6J mice as early as 1 week and 8 weeks after 
feeding, respectively (Lin et al., 2000). Obesity, T2D and metabolic syndrome are 
multifactorial and polygenic in their origins. Therefore HFD feeding strategy is 
advantageous over monogenically mutated rodent models. Nonetheless, HFDs with 
various concentrations of fat induce different degrees of obesity in mice. The extreme 
density of fat in diet (>60 kcal%) will result in greatest degree of obesity,which, however, 
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 is questioned by its physiological relevance (Buettner et al., 2007), as no human food 
contains such high calories.  
 
By feeding the Nedd4+/- and wild-type mice 60 kcal% fat HFD, and following the 
body weight changes in these mice for 9 months, we observed that: HFD induced 
significant weight gain in wild-type male mice after 1 week, while an obvious increase in 
body weight in Nedd4+/- male mice was observed at 4 weeks after feeding; there was a  
30% decline in the average weight gain in Nedd4+/- group of both genders at the end point 
of the study, though the female mice gained weight more slowly than male mice. Body 
weight difference between ND-fed Nedd4+/- and wild-type mice revealed significance 
with two-tailed student's t test, but not with two-way ANOVA with Bonferroni posttest 
correction when comparing between HFD and ND groups with both genotypes, 
suggesting that when diet was considered as a factor in addition to genotype, body 
weights between ND-fed Nedd4+/- and wild-type mice were not considered significantly 
different.  
 
 
6.1.1   The Energy Balance in Nedd4-haploinsufficient Mice 
 
In humans, dairy fat through the gastrointestinal tract is transformed to 
chylomicrons and lipoproteins, a portion of which is metabolized and utilized as energy 
supply and the rest is stored in adipose tissue for long-term storage (Shi and Burn, 2004). 
In light of the energy balance equation, obesity represents a form of energy surplus. It is 
commonly believed to be a result of either increased energy intake and/or decreased 
energy expenditure. The absolute calorie intake was reduced by 15% in Nedd4+/- male 
mice and by 12% in Nedd4+/- females compared to their respective wild-type controls. 
However, when adjusting daily calorie intake for per g body weight, we found no 
significant difference between gender-matched Nedd4+/- and wild-type mice. Basal 
phosphorylation levels of mTOR and AMPK in hypothalamus were similar between 
genotypes. Direct intracerebroventricular (i.c.v.) injection of leptin into mice evoked 
similar degree of increase in STAT3 phosphorylation in the two genotypes (see 
Appendix). These data suggest unaltered energy intake in HFD-fed Nedd4+/- mice 
compared to the wild-type controls. These data, however, do not rule out the possibility 
of altered energy absorption rate by the intestinal tract in Nedd4+/- mice on HFD, which 
requires taking the energy remnant in urine and feces into consideration.  
 
The body's thermogenesis at rest (basal metabolic rate) comprises a large 
proportion (60-70%) of energy expenditure. However, accurate measurement of the basal 
metabolic rate in mouse present a challenge, as the animals are small and their physical 
activities are impacted by environmental changes. In addition accurate analysis of the 
energy expenditure data versus body size is difficult, because it requires advanced 
equipment (Speakman, 2013). Nevertheless, alteration of basal metabolic rate is normally 
associated with changes in metabolism in BAT or skeletal muscle, which can be indexed 
by the expression of thermogenic genes and tissue mass. According to our analysis, the 
ratios of BAT and skeletal muscle weight to body weight were similar between genotypes 
with or without HFD feeding. Thermogenesis-related gene expression in BAT and 
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 expression of UCP1 in BAT, WAT or skeletal muscle were also unchanged by NEDD4 
downregulation. Moreover, physical activity as measured in afternoon by open-field test 
did not show any difference. These data suggest that the energy expenditure may be 
unaffected in the HFD-fed Nedd4+/- mice. Again, these data do not rule out a possible 
contribution of thermogenesis, as there might be activity change in Nedd4+/- mice during 
other untested time spectrum, considering the fact that mice are nocturnal animals. 
 
A third component in energy balance is the efficiency of energy storage. In times 
of positive energy balance, adipose tissue expands through adipogenesis and lipogenesis 
to store excess energy in the form of triglycerides, serving as a body defense against the 
overexposure of excessive lipid; in times of negative energy balance, adipose tissue is 
mobilized through the lipolysis process to release FFAs, which can be oxidized by other 
organs as fuel. We hypothesizes that the adipogenesis, lipogenesis, and/or the lipolysis 
pathways are altered in Nedd4+/- mice on HFD. Indeed, our data imply that the pathways 
of lipolysis and adipogenesis may contribute to the "lean" phenotype of HFD-fed 
Nedd4+/- mice. By performing in vivo and ex vivo lipolysis assays, we confirmed that at 
least the lipolytic action was increased in HFD-fed Nedd4+/- mice. In addition, knocking 
down NEDD4 in 3T3-L1 preadipocytes inhibited its conversion to mature adipocytes; we 
also observed an associated reduction of PPAR? expression levels in WAT in these mice, 
which implies that the adipogenesis process may be affected as PPAR? is the central 
adipogenic transcriptional factor.Besides adipogenesis and lipolysis, the de novo 
lipogenesis (DNL) is another important contributor to fat accumulation. DNL pathway 
can be activated by HFD and can take place in both liver and adipose tissue  (Strable and 
Ntambi, 2010). In our studies, Nedd4+/- mice were protected against HFD-induced liver 
steatosis, raising the possibility of decreased DNL in liver and/or adipose tissue. Indeed, 
the yeast homologue of NEDD4, Rsp5p, has been demonstrated to regulate unsaturated 
fatty acid synthesis (Hoppe et al., 2000). In Hoppe et al.'s study, they investigated the 
physiological outcomes in yeast cells harboring mutant Rsp5, and found that Rsp5 is a 
vital factor for the survival of yeast cells. To identify target genes for Rsp5, they screened 
strains carrying yeast library cDNAs to identify strains that could restore the toxic effects 
of Rsp5 deletion. Finally, the OLE1 gene which encodes stearoyl CoA desaturase (SCD, 
also called?9 fatty acid desaturase) was confirmed as a target gene of Rsp5 by 
ubiquitinating and activating the yeast transcription factors SPT23 and MGA2 
(homologous to mammalian NF-??). In mammals, SCD controls the synthesis of oleic 
acid, a form of monounsaturated fatty acids with important physiological functions. 
Intriguingly, depletion of SCD-1 protected mice against obesity and liver steatosis 
(Cohen et al., 2002; Ntambi et al., 2002), coincidently reminiscent of the Nedd4+/- mice 
phenotypes. Thus, it is of particular interest to investigate the effect of NEDD4 on 
lipogenic pathways. Particularly, it is interesting to see whether the effect of Nedd4 
haploinsuffciency on obesity is mediated through SCD, or through its interplay with 
PPAR? and other lipogenic and adipogenic factors. 
 
Using an obesity model induced by HFD, we demonstrate that NEDD4 is a 
modulator of lipid accumulation and is a novel regulator of adiposity in mice. Of note, 
drastic differences in weight gain between the two genotypes were only observed in 
HFD-fed group. Although we also observed a trend for decreasing body weight with  
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 aged-obese Nedd4+/- mice, the data failed to display statistical significance, presumably 
due to small cohort size and great individual variation. 
 
 
6.1.2   Peripheral Insulin Sensitivity in Nedd4-haploinsufficient Mice 
 
Cao et al. reported reduced insulin signaling in NEDD4 knockout MEFs. 
Similarly, we also observed decreased insulin sensitivity in Nedd4+/- mice at postnatal 
stage during ITT. Insulin signaling in several insulin-responsive organs of Nedd4+/- mice 
was also impaired. However, we did not observe significantly increased expression of 
either Grb10, as reported by Cao et al., or PTEN, a previously identified NEDD4 
substrate in cancer and neuronal cells (Kwak et al., 2010; Wang et al., 2007), suggesting 
cell-type-dependent substrate specificity for NEDD4. Despite the insulin tolerance defect, 
ND-fed Nedd4+/- mice were paradoxically glucose tolerant with normal basal blood 
glucose level. Collectively, the data suggest that ND-fed Nedd4+/- mice possess only 
mildly decreased insulin sensitivity, which may be compensated by increased insulin 
secretion through mild ? cell hypertrophy and/or hyperplasia. Surprisingly, chronically 
HFD-fed Nedd4+/- mice displayed the same degree of glucose intolerance despite lower 
circulating insulin levels, compared to HFD-fed controls. This dissociation of insulin 
resistance from body fat was observed in other murine models —such as the PPAR?2 
knockout (Medina-Gomez et al., 2007; Medina-Gomez et al., 2005; Zhang et al., 
2004),the Txnip knockout (Chutkow et al., 2010), the Pref-1 overexpressing (Lee et al., 
2003), and the adiponectin overexpressing (Kim et al., 2007)—which is similar to the 
phenotypes of ????????????? treatment (Lehrke and Lazar, 2005). The adiponectin 
transgenic mice on the ob/ob background exhibited expanded adiposity, which was, 
surprisingly, associated with improved metabolic outcomes, such as increased insulin 
sensitivity and glucose tolerance (Kim et al., 2007). While in the case of PPAR?2 
knockout and Pref-1 overexpressing mice, adipose mass was profoundly reduced, yet was 
associated with several metabolic abnormalities including insulin resistance. In contrast 
to the adipocentric view which considers the excessive fat storage as the main cause of 
insulin resistance and T2D (Cederberg and Enerback, 2003), these evidence suggest that 
the fat volume unlikely contributed directly to the obesity-associated insulin resistance. 
Rather, the expandability of adipose tissue and the ectopic lipotoxicity may be the 
primary factors linking obesity and insulin resistance (Virtue and Vidal-Puig, 2010). 
 
An unexpected finding from our work is that although Nedd4+/- mice on ND were 
resistant to insulin-mediated glucose clearance effect during ITT, GTT by i.p. glucose 
injection did not reveal difference between the two genotypes. This observation of 
impaired insulin tolerance yet normal glucose tolerance is coincidently similar to the 
phenotypes of PPAR?2 knockout mice, suggesting that NEDD4 and PPAR?2 might 
regulate overlapping molecular pathways in the control of insulin sensitivity(Zhang et al., 
2004). Furthermore, in a state of energy surplus evoked by HFD, Nedd4+/- mice were, 
paradoxically, protected against obesity, yet did not become more insulin resistant. In 
contrast to the deleterious effects on insulin sensitivity by 16 weeks of HFD seen in wild-
type mice, insulin sensitivity in Nedd4+/- mice as assessed by ITT did not further 
deteriorate.These phenotypes are, again, reminiscent of the phenotypes of PPAR?+/- mice; 
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 these mice were protected against obesity an insulin resistance induced by HFD (Kubota 
et al., 1999). Our Western-blot analysis of PPAR? protein levels in adipose tissue from 
Nedd4+/- and wild-type mice under HFD-fed or aged conditions revealed a positive 
correlation between NEDD4 and PPAR? levels, though the changes in PPAR? expression 
levels under aged condition failed to achieve statistical significance. The levels of 
NEDD4 were better correlated with PPAR?2 than with PPAR?1 under HFD-fed 
condition, but were correlated similarly with both isoforms under aged condition. These 
results imply that NEDD4 may be an upstream regulator of PPAR?, and that the 
metabolic effects of NEDD4 may be mediated through PPAR?, especially PPAR?2.  
 
In terms of the discrepancy that the "insulin resistant predisposed"Nedd4+/- mice 
did not become more insulin resistant, as is also the case with PPAR?+/- mice, one 
possible explanation might be that these mice already had reduced insulin sensitivity on a 
ND; the molecular mechanisms through which their partial deficiency leads to insulin 
resistance on the ND are very similar to the mechanisms underlying insulin resistance 
induced by a HFD, and therefore insulin resistance did not become further impaired 
(Medina-Gomez et al., 2005). Another possibility is that reduced adiposity in HFD-fed 
these mice could result in a modest improvement in insulin sensitivity, which might 
compensate the additive effect of haploinsufficiency on HFD-induced insulin resistance. 
Mechanisms underlying these phenotypes thus far only partially understood.  Deeper 
understanding of the regulation, signaling, and tissue-specific roles of NEDD4 could 
provide novel mechanistic insights and new therapeutic targets for its actions related to 
obesity and insulin resistance.  
 
 
6.1.3   Regulation of Lipolysis by NEDD4 
 
A study conducted by Langin et al. showed that obesity is associated with 
resistance to catecholamine-induced lipolysis (Langin et al., 2005), suggesting that 
enhancing lipolytic rate is a potential strategy to remove fat and treat obesity. Although 
there is a widespread acceptance of the notion that an increase in lipolysis would result in 
facilitated release of FFAs into bloodstream, thereby mediating several adverse metabolic 
effects, including insulin resistance (Nielsen et al., 2004). This idea is now being 
challenged by recent studies. Clinically, even severe insulin resistance, can coexist with 
obesity with no alteration in FFA levels. On the other hand, increased levels of FFAs are 
not necessarily associated with insulin resistance (Karpe et al., 2011), suggesting that the 
increased levels of plasma FFA associated with obesity is a consequence rather than a 
cause (Byrne et al., 1999). Furthermore, enhanced lipolysis does not change serum FFAs 
levels, as demonstrated in several murine models(Ahmadian et al., 2009; Ahmadian et al., 
2010; Jaworski et al., 2009; Saha et al., 2004; Tansey et al., 2001). Therefore, promoting 
fat loss by enhancing lipolysis may still be an intriguing strategy for the treatment of 
obesity.  
 
In human, catecholamines mainly epinephrine and norepinephrine are the 
hormones with pronounced lipolytic action via the seven transmembrane protein ?-AR. 
????????????????-AR subtypes have been identified including —?1-?????2-AR and ?3-AR. 
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 The ?-AR-mediated lipolytic process in adipose has been extensively studied in human 
and rodent adipocytes. However, the human and rodent adipocytes have differential 
responsiveness to ?3-AR agonists to activate the lipolysis pathway. Human adipocytes 
respond much less efficiently to the ?3-AR agonist. Functional assays by applying ?-
agonists indicate that catecholamines primarily activate ?1-AR and ?2-AR, rather than the 
?3-AR in both white and brown adipocytes from rats (Bahouth and Malbon, 1988; 
Galitzky et al., 1995). Although the ?3-AR is the only ?-AR specifically expressed in fat, 
RT-PCR results from a previous report suggest that ?1-AR and ?2-AR are the major 
subtypes in the subcutaneous adipose tissue from rat (McNeel and Mersmann, 1999), 
consistent with the functional assays. Our studies show that isoproterenol-stimulated 
lipolytic response in Nedd4+/- mice on HFD is remarkably higher than that from their 
wild-type littermates on HFD. Since the ?3-AR subtype does not significantly contribute 
to isoprenaline-induced lipolysis (Tavernier et al., 1996). We thereby speculate that the 
effect is primarily through ?1- or ?2-AR. 
 
The ?-AR belongs to a G protein coupled receptor (GPCR) family. Sustained 
???????????????????-ARs leads to receptor desensitization and/or degradation. While the 
?1-AR is believed to be resistant to agonist-induced ubiquitination and degradation 
(Liang and Fishman, 2004), the E3 ligase-mediated ubiquitination of ?2-AR plays an 
important role in regulating the abundance of the receptor. NEDD4 is known to be 
recruited to the agonist-???????????2-??????????????????????????????-arrestin 2 and 
arrestin-domain-containing proteins (ARRDCs), especially ARRDC2-4 (Han et al., 
2013b; Nabhan et al., 2010; Shenoy et al., 2008). Shenoy et al. demonstrated that MDM2 
mediates ubiquitination of ?2-AR and their adaptor protein ?-arrestin 2 which regulates 
the initial step of receptor endocytosis (Shenoy et al., 2001), and NEDD4 mediates 
subsequent receptor ubiquitination which targets receptors for lysosomal degradation 
(Shenoy et al., 2008). Although discrepant results from Nabhan et al. suggest that 
ARRDC3, rather than ?-arrestin 2, serves as the adaptor protein (Nabhan et al., 2010), 
both studies are not mutually exclusive in that they unequivocally delineate the role of 
NEDD4 in downregulating ?2-AR. Later, Han et al. demonstrated that the ?-arrestin 2 is 
the first adaptor protein between NEDD4 and ?2-AR to facilitate clathrin-dependent 
internalization, while the ARRDCs serve as the secondary adaptors lead the NEDD4 and 
?2-AR complex to the early endosome (Han et al., 2013b). Interestingly, ARRDC3-
?????????? ??????????????????????????????????????????????????? ???????????-adrenergic 
signaling (Patwari et al., 2011). In spite of the fact that NEDD4 has a substantial number 
of substrates, very few in vivo studies have been reported to validate its 
pathophysiological relevance. It should be stressed that our work, for the first time, 
demonstrates a physiological role of NEDD4-??????????2-AR signaling in the context of 
lipolysis.  
 
Even though agonist-stimulated lipolysis was higher in the HFD-fed Nedd4+/- 
mice, circulating lipid concentrations did not increase. This is consistent with phenotypes 
reported in adipose ATGL transgenic mice (Ahmadian et al., 2009), adipocyte 
phospholipase A(2) (AdPLA) knockout mice (Jaworski et al., 2009), perilipin knockout 
mice (Saha et al., 2004; Tansey et al., 2001). In these mice, the serum FFAs levels were 
not altered, even though they all exhibited enhanced lipolysis. Reduced adipose mass 
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 could have resulted in lower basal FFA release, which might have compensated for the 
elevated lipolysis in the HFD-fed Nedd4+/- mice. ??????????????????????????-oxidation at 
ectopic sites could have maintained the circulating lipid homeostasis, although in the 
current study, we do not have evidence to support this hypothesis. In agreement with our 
speculation, the murine models mentioned above all exhibited enhanced ?-oxidation at 
least in adipose tissue (Ahmadian et al., 2009; Jaworski et al., 2009; Saha et al., 2004). 
One discrepancy from these studies is that, we only observed enhanced lipolysis in HFD-
fed Nedd4+/- mice under the stimulation ?-agonists, while the basal lipolysis appears to be 
unaffected, which implies that the altered lipolysis in these mice is ligand dependent. 
This may also explain the discrepancy that the lipolytic response was only affected in the 
HFD-fed or aged animals, as chronic dietary fat or aging could act as a stressor that 
stimulates sympathetic nerve activity, releasing catecholamines which facilitates energy 
expenditure pri??????????????????????????????????-AR mediated lipolysis (Lowell and 
Bachman, 2003).  
 
 
6.1.4   Regulation of Adipogenesis by NEDD4 
 
Chronic adipose tissue remodeling represents a fundamental and highly 
coordinated process involving the participation of different cell types, including 
endothelial precursors, immune cells, and preadipocytes (Sun et al., 2011). In mice at an 
earlier stage of obesity (within the 16-week design of HFD feeding), adipose tissue 
expands primarily through hypertrophy. At later stages (after 16 weeks of HFD feeding), 
a high degree of adipocyte apoptosis (approximately 80%) becomes evident, so that 
adipose expansion relies on hyperplasia (Strissel et al., 2007).  
 
Adipogenesis contributes to the expansion of adipose tissue; therefore, 
pharmacological intervention to inhibit adipogenesis appears to be a logically promising 
approach to restrain obesity. However, factors that impede adipocyte growth and 
expansion also lead to metabolic defects (Stephens, 2012). For example, Pref-1 is a 
negative regulator of adipogenesis secreted by preadipocytes; Pref-1 transgenic mice are 
insulin resistant despite its resistance to HFDIO (Villena et al., 2008). Another example is 
PPAR?2 knockout mice, which also display insulin resistance (Medina-Gomez et al., 
2007); PPAR?2 is generally believed to be more effective in pro-adipogenesis than 
PPAR?1. Hence, factors that limit adipose expansion without altering insulin sensitivity 
should receive more attention since they represent a promising strategy for weight loss. 
 
Although our work has revealed that NEDD4 and ????? expressions are 
positively correlated and that these two proteins can be co-immunoprecipitated, future 
studies must consider the following key questions. Are the NEDD4 and PPAR? 
physically interacted, or through an adaptor? Does the NEDD4-??????????????????
account for NEDD4’s ???????????????????????????????Where does the interaction occur? 
What is the physiologic consequence of attenuating the NEDD4-??????????????????
during adipocyte differentiation? During our investigation, a study from Han et al. 
reported the physical interaction between PPAR? and NEDD4 through PPxY motif in an 
overexpression in vitro system. They claimed that NEDD4 is the ??????????????????? in 
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 response to the ???-estradiol treatment in HeLa cells (Han et al., 2013a). However, in our 
study, we did not see a significant reduction in PPAR? levels by NEDD4 overexpression, 
suggesting that PPAR? is subjected to the regulation of different E3 ligases under 
different conditions. In the current study, we observed in vitro that knockdown of 
NEDD4 in 3T3-????????????????????????????????????????????????????????????????
adipogenesis. We propose that ???????????????????????????????????? in preadipocytes 
when PPAR??level is low, prohibiting its degradation by other E3 ligases, whereas 
?????????????????????????????? and releases it for nuclear translocation and 
transactivation (Hauser et al., 2000) during the adipocyte differentiation process (Figure 
6.1). Due to the high lipid content of adipose cells, it is technically difficult to study 
???????????????????????????????????in vivo. Using the 3T3-L1 preadipocytes, Thuillier et 
al. ??????????????????????????????evenly in the cytosol and nucleus of the preadipocyte; 
????????????????????????????????????????????????????????????????????????????????????????
within the nucleus (Thuillier et al., 1998). Localization of NEDD4 in adipocytes has not 
been reported, but NEDD4 localizes to both cytoplasm and nucleus in most cell types. 
???????????????????????????????????????????????????????????????????????????????????
NEDD4’s effects on lipolysis and adipogenesis can be reproduced in vitro (at least in 
3T3-L1 cells), these observations are unlikely to be secondary consequences from other 
organs, such as muscle and liver. Tissue-specific signaling and function of NEDD4 are 
worthy for further investigation using conditional knockout mice. 
 
 
6.1.5   E3 Ligases in Metabolism 
 
E3 ligase is the final step for the conjugation of ubiquitin to substrates managing 
the selection of targets, and therefore has been substantially studied in diseases with 
abnormal protein accumulation, such as neurodegeneration and cancer (Ardley and 
Robinson, 2004; Sun, 2003). There has been very limited investigation of this class of 
enzymes for the metabolic functions. Rsp5p, the most well-studied yeast E3 ligase, 
participates in the process of unsaturated fatty acid synthesis (Hoppe et al., 2000). Its 
mammalian homologues—NEDD4 and ITCH (also called AIP4)?are two structurally 
related E3 ligases belonging to the nine-member HECT NEDD4 family. NEDD4 and 
ITCH both recognize the proline-rich consensus sequence motifs (e.g., PPxY and PPLP) 
and thereby ubiquitinate several overlapping targets in vitro (Bray, 2006), including the 
RING-type E3ligase Cbl-b (Magnifico et al., 2003). Comparative study of immunity 
using genetically modified mice indicates that NEDD4 and ITCH regulate distinct 
pathways in vivo (Yang et al., 2008). Recently, depletion of ITCH in mice has been found 
to reverse HFD-induced obesity and its related metabolic disorders, as well as an aberrant 
M2 macrophage polarization (Marino et al., 2014). Our work shows that NEDD4 partial 
depletion also attenuates HFDIO progression and pro-inflammatory response, likely 
through decreased M1 macrophage recruitment. These findings suggest that distinct 
metabolic and inflammatory pathways regulated by NEDD4 and ITCH may converge to 
produce an anti-obese action. The NEDD4/ITCH and Cbl-b were frequently found to be 
mutually impeded in previous studies (Guo et al., 2012; Thien and Langdon, 2005). 
Coincidentally, Cbl-b depletion caused aggravated HFD-induced insulin resistance and 
macrophage recruitment (Abe et al., 2013; Abe et al., 2014), consistent with its inverse  
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 Figure 6.1  Schematic Diagram of NEDD4 Regulation of Lipolysis and Adipogenesis. 
Under pathological conditions such as aging or HFD-induced obesity, plasma levels of 
catecholamine and FFA increase. The increased presence of catecholamine promotes 
ligand-induced endocytosis and degradation of ?2-AR mediated by NEDD4, resulting in 
fewer receptors on the surface of adipocyte and reduced lipolysis. On the other side, 
elevated FFA uptake into adipocyte provides more ligands for PPAR?. NEDD4 interacts 
??????????????????????prohibiting its degradation by other E3 ligases and facilitates 
adipogenesis mediated through PPAR? and RXR as heterodimer. Although detailed 
regulation of this process by NEDD4 await further investigation. 
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 relationship to NEDD4/ITCH. The crosstalk of molecular pathways among these three E3 
ligases in obesity is still waiting to be further investigated. 
 
 
6.2 Physiological Role of NEDD4 in CNS 
 
 
6.2.1   Nedd4 Haploinsufficiency Leads to Altered Cognitive and Anxiety-like 
Behaviors 
 
In our studies, adult Nedd4+/- mice showed significant impairment in behavioral 
by the water maze test. Overall tissue pathological alteration was not observed. 
Previously, Nedd4+/- mice were reported to have deficits in the development of cardiac 
and neuromuscular junction (Fouladkou et al., 2010; Liu et al., 2009). This raises the 
question that if the impaired water maze performance in Nedd4+/- mice might be 
unrelated to their cognitive functions. In our current study, physiological parameters, 
such as organ weights, in Nedd4+/- mice were similar to those of wild-type counterparts. 
During the visible platform training, Nedd4+/- mice performed well but only displayed 
impairment in the hidden section. This pattern of behavior indicates that the Nedd4+/- 
mice does not have visual problems and suggest a cognitive deficit. These findings 
implicate NEDD4 in certain unidentified processes underlying neuritic plasticity in the 
mammalian brain, involving the hippocampal formation. This is the first physiological 
evidence of NEDD4 in potential regulation of learning and memory. 
 
As Nedd4+/- mice performed differently in cross maze, fear conditioning and 
water maze, we are unable to conclude so far whether this discrepancy is a result of the 
different settings in experimental paradigms or indicates a differential regulation of short- 
term and long-term memory by endogenous NEDD4. Future studies may need to include 
more behavioral tests to assess their learning and memory ability in different 
environments. In the current study, we also demonstrated that NEDD4 is involved in the 
development of anxiety-like behaviors as judged by open-field and light/dark box tests. 
The mechanisms underlying these neurobehavioral changes remain unknown. It should 
be pointed out that water maze test is well known to cause severe anxiety on mice; mice, 
compared to rats, have intrinsic fear of water.  Therefore, in this case, water maze may 
not be a suitable test for long-term memory. Instead, a dryland version called Barnes 
maze test should be used to clarify whether Nedd4+/- mice indeed have impaired long-
term memory. 
 
 
6.2.2   Central Insulin Signaling in Nedd4–haploinsufficient Mice 
 
Insulin and IR signaling are known to play critical roles in the process of learning 
and memory (Zhao and Alkon, 2001; Zhao et al., 2004), however, examination of insulin 
sensitivity locally in the hippocampus, especially in the adults, presents a challenge. 
Because brain is extremely sensitive to hypoxia; death of neurons is prominent even 
immediately following the isolation of the brain. To test the central insulin signaling in 
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 Nedd4+/- mice, we tried to administer insulin through i.p., intravenous (i.v.), and i.c.v. 
routes. None of these methods provided reasonably accurate measurements. Due to the 
existence of blood brain barrier, large molecules like insulin cannot be efficiently 
delivered to the brain through i.p. or i.v. injection, since its transport requires a saturable 
transporter (Banks et al., 1997). The concentration of insulin in the brain is, therefore, 
largely dependent upon the transport efficiency. Insulin signaling is an acute effect which 
can trigger phosphorylation events within 5 min of exposure to insulin. Furthermore, 
hippocampus is less sensitive to insulin than regions like hypothalamus. Therefore, i.p. or 
i.v. injections of insulin only induced a very mild degree of phosphorylation in IR in 
hippocampus; also, a large variation between individual mouse was shown which is 
likely due to the different transport efficiency of insulin in each mouse.  
 
I.c.v. injection allows insulin to merge locally to the cerebrospinal fluid within 
cerebral lateral ventricle and circulate to hippocampus. We did see a robust induction of 
IR phosphorylation with i.c.v. injection. However, the data were difficult to interpret as 
we saw increased IR phosphorylation levels in Nedd4+/- mice, which are opposite to the 
peripheral insulin signaling data. We suspect that the ketamine/xylazine which we used to 
anesthetize the mice before surgery may have compromised our data, as ketamine and 
xylazine have been implicated in the regulation of insulin sensitivity (Heim et al., 2002; 
Xiao et al., 2013). In the present study, we stimulated the cortical tissue isolated from P0 
mice with insulin. Use of cortical tissue from neonatal mice has the advantage of being 
relatively resistant to hypoxia therefore the isolated tissue not need for oxygen 
supplement within the first 2 hours to maintain the viability of neurons. Shortcomings are 
that the response only represents neonatal mice but not adult mice and that it is difficult 
to study region-specific effects.  
 
 
6.3 Future Studies 
 
As discussed previously, to better solve mechanistic puzzle of tissue-specific 
regulation by NEDD4 in adipocyte, a conditional knockout of NEDD4 in adipose tissue 
can be considered. This will help circumvent the potential problems from CNS controls, 
as the WAT is innervated by the sympathetic nervous system (SNS). Bioinformatics tools 
including next generation RNA sequencing and proteomics may be employed to further 
delineate cell-type specific substrates of NEDD4 in adipocytes. 
 
To improve data quality, the metabolic cages could be considered for measurement 
of basal metabolic rate and energy intake where the energy remnant in the urine and feces 
can be carefully subtracted; a Dual-energy X-ray absorptiometry technique could be 
utilized to measure lean/fat mass ratios and the hyperinsulinemic-euglycemic clamp 
technique may be employed to assess insulin sensitivity. In addition, lentivirus has been 
reported to have better infection rate than AAV for 3T3-L1 cells and therefore, may 
improve the knockdown efficiency of NEDD4 and produce more significant results. 
Alternatively, inducing adipogenesis using NEDD4 knockout MEF cells may be 
considered. However, it should be noted that the differentiation efficiency in primary 
MEFs varies from 10-70% and immortalized MEF cells normally require the 
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 overexpression of a pro-adipogenic transcription factor such as PPAR? or C/EBP? 
(Rosen and MacDougald, 2006). Future experiments could be designed to analyze the 
interaction sites between NEDD4 and PPAR? and clarify the physiological relevance of 
their interaction. It would be of particular interest to see the metabolic outcome in mice or 
adipocytes with the expression of PPAR? lacking the binding sequences for NEDD4. 
 
The Nedd4+/- mice are partially protected against HFD-induced obesity, implying 
that NEDD4 may mediate the development of obesity to some extent. Surprisingly, the 
several metabolically active tissues (hypothalamus, skeletal muscle and WAT) from 
HFD-fed mice is not associated with aberrant NEDD4 protein expression. We speculate 
that NEDD4 may be altered in a specific cell type (e.g. the preadipocytes). If so, 
measuring the expression of NEDD4 in tissues with mixed cell types may yield false 
information. Another plausible explanation is that NEDD4's activity is changed rather 
than its expression levels. NEDD4 protein contains multiple catalytic cysteine residues 
which are vulnerable to oxidative stress normally associated with obesity. 
 
To confirm the behavioral phenotypes of Nedd4+/- mice, additional behavioral 
tests such as Barnes maze, Y maze, and novel object recognition tests for spatial learning 
and memory may be considered. Moreover, elevated plus maze and novelty-suppressed 
feeding test may be performed to validate the anxiety-like behavior in Nedd4+/- mice. 
Single-cell RNA sequencing and proteomics which avoid glial cell contamination may be 
considered for further delineation of NEDD4 substrates in neurons. Future investigation 
of insulin signaling in adult brain may consider using acute hippocampal slice preparation 
following tissue slice electrophysiology experiments. This technique circumvents 
contamination from anesthetics and reduces animal use, as both dose- and time-response 
studies can be performed in slices from a single mouse.  
 
 
6.4 Using Heterozygous Mouse as Models—Advantages vs. Disadvantages 
 
Over the past two decades, genetically modified mice have provided us with 
tremendous advantages in studying physiological functions of molecules in vivo (in 
mammals), more specifically by manipulating their gene expression. Currently, 
conditional knockout and transgenic technologies enable researchers to specifically delete 
or overexpress certain genes at particular stages of life. In addition, it allows researchers 
to do so in a tissue-specific or cell-type specific manner. These available technologies 
greatly advance our understanding of the patho-physiological roles of a certain molecule 
or molecular pathway in areas and at times of interest. However, limitations of this 
technique remain with respect to controlling the expression level of a transgene, which 
are so called dosage-dependent effects. Therefore, caution should be taken when 
interpreting mouse phenotypes. For example, when knocking out a certain gene resulting 
in morbidity or mortality, it is not implicit that its overexpression will necessarily lead to 
beneficial effects. Often, to study a gene’s expected function by complete knockout or 
overexpression may be compromised by embryonic lethality as in the case of Nedd4-/- 
mice. The embryonic lethality indicates the crucial role of NEDD4 in IGF-1 signaling of 
the early developmental stages, while overexpression of NEDD4, as in the case of 
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 neurodegeneration, leads to impaired IGF-1 signaling due to its role as the E3 ligase of 
IGF-1R. Ultimately knockout and overexpression approaches are often used to study 
physiological and pathological functions of a molecule, respectively. Expressing a 
transgene at “right dosages” is of particular importance especially in disease-related 
research. 
 
Because it is uncommon for human molecules to be completely knocked out or 
overexpressed, a more practical approach for study entails heterozygosity.  In our studies, 
we used a Nedd4 heterozygous mouse model to characterize the role of the Nedd4 gene in 
metabolism and CNS functions. Though partial depletion of Nedd4 was sufficient to 
produce a certain degree of metabolic phenotypes, the phenotypes observed were 
generally mild. For example, Nedd4+/- mice exhibited moderate insulin resistance, 
because their glucose clearance responded less efficiently to insulin during ITT. 
Additionally, they had slightly higher serum insulin levels when compared to their wild-
type littermates. Nedd4+/- mice were only partially resistant to HFD-induced obesity (30% 
reduction in weight gain) without improvement in obesity-associated insulin resistance, 
hyperglycemia, and hyperlipidem?????????????????????????????????????????????? ????
50%. Although using a diet with a lower percentage of calories from fat may help enlarge 
the difference, whether these phenotypes or results can become more dramatic or 
significant when Nedd4 is completely depleted is unknown. We believe that WAT is the 
most selectively affected tissue under obesogenic conditions as demonstrated by our ex 
vivo and in vitro data. Using heterozygous mice for an initial characterization offers 
insight to the potential pathways affected. Further studies using tissue-specific 
conditional knockout mice will be necessary to fully validate our hypotheses, which may 
further advance our knowledge of the biological functions of NEDD4 in metabolism.  
 
One should bear in mind the potential artifacts of the observed phenotypes 
displayed through a genetically manipulated mouse model. The specificity of knockout or 
knockdown effects in gene-trap studies has been questioned, because these mice are 
hybrid in origin with both B6 and 129 type alleles. The 129-type alleles could also 
contributes to the changes in phenotypes (Muller, 1999). The mutant mice in our present 
study were heterozygous for not only the Nedd4 locus, but also the flanking region (B6 × 
129). It has been reported that the C57BL/6J (B6) mouse strain was more prone to 
obesity, while the 129Sv strain was both obesity- and diabetes-resistant. Accordingly, 
their intercross (B6 × 129) F2 mice were more obese-prone than 129 mice (Almind and 
Kahn, 2004). In terms of neurobehavior, F1 hybrids of B6 and 129 strains perform better 
than both inbred B6 and 129 strains in learning and memory tasks (Crawley et al., 1997). 
Therefore, the resistance to diet-induced obesity and the behavioral deficits observed in 
the Nedd4+/-mice of B6 × 129 hybrid origin are not likely explained by the contribution of 
129-type alleles. 
 
 
6.5 E3 Ligase as Drug Target 
 
Dysregulation of UPS is associated with a number of hard-to-treat diseases, 
including cancer, neurodegeneration, viral infection, muscle atrophy, and diabetes and 
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 inflammation. The reversible proteasome inhibitor bortezomib (Velcade®) was the first 
FDA approved drug for the treatment of both multiple myeloma and mantle cell 
lymphoma (Adams and Kauffman, 2004). The following year, the Nobel Prize in 
Chemistry was awarded to jointly to Aaron Ciechanover, Avram Hershko, and Irwin 
Rose for their discovery of UPS pathway (The official website of the Nobel Prize). In the 
past decade, UPS-pathway-targeting compounds against more precise targets have 
emerged as novel candidates for drug discovery. Considering the fact that humans 
possess two E1 enzymes, ~30 E2 enzymes and several hundreds of E3 ligases, 
compounds that target E1, or E2 enzymes are hopeless due to lack of specificity, and 
thereby could result in undesirable side-effects. E3 ligases control the specificity of 
substrate ubiquitination, making this class of enzymes the most appealing targets for drug 
development. However, the E3 ligase targeting drug discovery process is still in its 
infancy due to the complexity of UPS regulations (Wilkie et al. 2012). Our studies 
provide experimental evidence for the involvement of NEDD4 E3 ligase in several 
biological processes (lipolysis, adipogenesis, insulin signaling, learning/memory, and 
anxiety), which may facilitate our understanding of complex E3-ligases-mediated UPS 
regulation in the context of physiological and pathological settings.  Full investigation of 
each pathway in greater details at molecular levels will be instrumental to future 
validation of NEDD4 as a suitable drug target.   
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 APPENDIX: SUPPLEMENTAL INFORMATION 
 
 
For i.c.v. injection of leptin, anesthetized mouse was placed on a stereotaxic frame 
paded with a heating pad set at 37 °C. The head of mouse was fixed on a palate suppor by 
the ear bars. A small incision was made through the midline of the scalp to expose the 
bregma and lamda. The angle of head was ajusted to ensure that the bregma and lamda 
were in the same horizonal level. The skull was then punctured at a desired localization 
with a mini drill. A 10 ?l Hamilton syringe was loaded with leptin and inserted into the 
lateral ventricle of the brain for the injection (stereotaxic parameters: -0.7?mm anterior-
??????????????? ?? ?????-lateral, and -1.9?mm dorsal-ventral). A total volume of 2 ?l of 
leptin (5 ?g/?l) was injected slowly throught via syringe in 5 min. The syringe was left 
untouched for an additional 5 min after the injection, and then slowly pulled away. After 
30 min, mouse was euthanized; hypothalamus was isolated and snap-frozen until use. 
Tissue lysates were subjected to Western-blot analysis (Figure A.1). 
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Figure A.1 AMPK, mTOR, and Leptin Signaling in Hypothalamus of Nedd4-
haploinsuffcient Mice. 
(A) Phosphorylation levels of STAT3 by leptin stimulation in the hypothalamus and 
hippocampus (n=4).(C) Phosphorylation levels of mTOR (Ser2448) and AMPK (Thr172) 
in hypothalamus in ND-fed mice between 12-16 weeks (n=3). (B) Quantification bar for 
A. (D) Quantification bar for C. Data represent mean ± SEM; n.s. no significance. 
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